A Phase 4 interventional study of Levodopa-carbidopa intestinal gel (LCIG) and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Idiopathic Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-07-18.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2006, is the only one in phase 4, and was the 1st registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Croatia and 6 more countries
Ages 18–69
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in Spain
Ages 18+
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Germany
Ages 18–67
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 63 across the 25 interventional studies, 131 across the 18 observational. Of the 33 that completed or were terminated, 18 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
5 of the studies in Parkinson Disease by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT06639620AbbVieStudy To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | 2027-03 |
| NCT06965374AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | 2027-06 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Parkinson Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)
Duodopa non-naïve participants treated with Duodopa for \< 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)
Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)
Also known as: DUOPA™ (carbidopa and levodopa Enteral Suspension), DUODOPA®, ABT-SLV187
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect); for Part IV, questions are measured on a 5- or 2-point scale (0 or 1). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.
Time frame: Baseline (Month -3), Month 12
Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score at Baseline and Month 12
The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 (worst health state) to 1.00 (perfect health state).
Time frame: Baseline (Month -3), Month 12
EQ-5D Visual Analog Scale (VAS) Score at Baseline and Month 12
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state.
Time frame: Baseline (Month -3), Month 12
Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010
Total monthly costs include * Direct medical costs (inpatient care, outpatient care, and drug costs \[including Duodopa cost and cost of concomitant anti-PD medication\]). * Direct non-medical costs (nursing home, home help, personal assistance, informal care \[from family member or friend\] and transportation to inpatient, outpatient visits and nursing home). * Indirect costs (sick-leave and early retirement due to PD \[applied to individuals only up to the age of 65 since the main indirect cost item, early retirement due to disability, is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden\]). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Monthly Drug Costs Per Participant, SEK 2010
Drug costs include Duodopa cost and cost of concomitant anti-PD medication. Drug costs are a direct medical cost. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010
Direct medical costs consist of inpatient care, outpatient care (visits to physician, nurse, physiotherapist, occupational therapist, dietitian, speech therapist, counselor, and phone consultations). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Direct Monthly Non-medical Costs Per Participant, SEK 2010
Direct non-medical costs include nursing home, home help, personal assistance, informal care (from family member or friend) and transportation to inpatient, outpatient visits and nursing home. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Indirect Monthly Costs Per Participant (Only Applied to Participants Younger Than 65) by Study Month, SEK 2010
Indirect costs consist of sick-leave and early retirement due to PD, are applied to individuals only up to the age of 65 since the main indirect cost item - early retirement due to disability - is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until Month 36
Modified Hoehn and Yahr Staging: Current Stage From Baseline to Month 36
The current stage of PD was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Modified Hoehn and Yahr Staging: Best Stage From Baseline to Month 36
The best PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Modified Hoehn and Yahr Staging: Worst Stage From Baseline to Month 36
The worst PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Schwab and England Scale: Best "On" Period Stage From Baseline to Month 36
The Schwab and England scale was used to rate the subject's best "on" period during the past week by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%). "On" time is when PD symptoms are well controlled by the drug.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Mini Mental Status Examination (MMSE) Total Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score of 0 to 30, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint visit (Month 36 or last visit if discontinued early)
MMSE Orientation Subscale Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The orientation subscale has a total possible score of 0 to 10, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MMSE Registration Subscale Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Registration subscale a total possible score of 0 to 3, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MMSE Attention and Calculation Subscale Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Attention and Calculation subscale results in a total possible score of 0 to 5, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MMSE Recall Subscale Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Recall subscale results in a total possible score of 0 to 3, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MMSE Language Subscale Scores From Baseline to Month 36
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Language subscale results in a total possible score of 0 to 9, with higher scores indicating better function.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Total score ranges from 0 (no depression) to 60 (severely depressed).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Reported Sadness Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reported Sadness scores rate depressed mood, regardless of whether it is reflected in appearance or not, and includes low spirits, despondency or the feeling of being beyond help and without hope.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Apparent Sadness Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Apparent sadness scores rate despondency, gloom and despair (more than just ordinary transient low spirits), reflected in speech, facial expression, and posture.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Inner Tension Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inner Tension scores rate feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Reduced Sleep Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Sleep scores rate the experience of reduced duration or depth of sleep compared to the participant's own normal pattern when well.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Reduced Appetite Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Appetite scores rate the feeling of a loss of appetite compared with when-well. Rate by loss of desire for food or the need to force oneself to eat.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Concentration Difficulties Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Concentration Difficulties scores rate difficulties in collecting one's thoughts mounting to an incapacitating lack of concentration.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Lassitude Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Lassitude scores rate difficulty in getting started or slowness in initiating and performing everyday activities.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Inability to Feel Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inability to Feel scores rate the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is reduced.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Pessimistic Thoughts Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Pessimistic Thoughts scores rate thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
MADRS Suicidal Thoughts Scores From Baseline to Month 36
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Suicidal Thoughts scores rate the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible, which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Mobility Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Activities of Daily Living Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Emotional Well Being Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Stigma Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Social Support Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Cognition Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Communication Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
PDQ-39 Bodily Discomfort Subscale Scores From Baseline to Month 36
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Walking) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Walking scores ranged from 1 (worst) to 5 (best).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Off Time) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "Off" time is when PD symptoms are not adequately controlled by the drug, and is represented as a percentage of total time awake per day.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (On Time) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "On" time is when PD symptoms are well controlled by the drug, and is represented as a percentage of total time of the last __ hours.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Dyskinetic Time) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement, and is represented as a percentage of total time of the last __ hours.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Off Magnitude) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Off time' is when PD symptoms are not adequately controlled by the drug. Magnitude scores were 1 (worst) to 5 (best).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Dyskinetic Magnitude) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement. Magnitude scores were 1 (worst) to 5 (best).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Cramps) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Cramps' scores were 1 (worst) to 5 (best).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Satisfied With Function) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Satisfied with function' scores were 1 (worst) to 5 (best).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Self-assessment) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Self-assessment' scores were -3 (Off) to +3 (dyskinetic). 'Off' time is when PD symptoms are not adequately controlled by the drug. 'Dyskinetic' time is time with involuntary muscle movement. "0" is defined as the normal ON state without dyskinesia (the desired motor state). Everything closer to "0" means improvement, everything more away from "0" means either less mobility (in the negative score) or involuntary movements (dyskinesia, in the positive score).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Free Tapping - Speed) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Free tapping is defined as voluntary repetitive finger tapping on computer-generated fields. 'Free tapping speed' is a count of the number of taps per 20 seconds.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Free Tapping - Accuracy) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Free tapping' is defined as ____. 'Free tapping accuracy' is the percentage of accurate free taps per 20 seconds(?).
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Tapping, Increased Speed - Accuracy) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Tapping at increased speed - accuracy' is the percentage of accurate taps per all taps on computer-generated fields.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Speed) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Accuracy) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds. 'Tapping random chase - accuracy' is the percentage of accurate random chase taps.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Electronic Diary: Morning and Day Scores (Drawing Impairment [Wavelet Method]) From Baseline to Month 36
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Drawing impairment was assessed as a spiral score, where the participant is asked to draw a spiral. 1 is worst score, 10 is best.
Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
UPDRS Total Score up to Month 36
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
UPDRS Part I Score, up to Month 36
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Higher scores are associated with more disability.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
UPDRS Part II Score, up to Month 36
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Higher scores are associated with more disability.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
UPDRS Part III Score, up to Month 36
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Higher scores are associated with more disability.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
UPDRS Part IV Score, up to Month 36
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Part IV, questions are measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect) or 2-point scale (0 or 1). Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Higher scores are associated with more disability.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
EQ-5D Descriptive Systems Summary Index Score, up to Month 36
The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
EQ-5D Visual Analog Scale (VAS) Score, up to Month 36
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'
Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
| Milestone | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Started | 37 | 22 | 18 |
| Safety sample | 36 | 22 | 18 |
| Full analysis sample | 27 | 22 | 18 |
| Completed | 21 | 16 | 12 |
| Not completed | 16 | 6 | 6 |
| Withdrew: Withdrew consent prior to treatment | 1 | 0 | 0 |
| Withdrew: Adverse event | 7 | 5 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 5 | 0 | 0 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect); for Part IV, questions are measured on a 5- or 2-point scale (0 or 1). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Total Score, Baseline (Month -3); n=27, 0, 0 | 52.1 ± 16.1 | NA ± NA | NA ± NA |
| Total Score, Month 12; n=25, 20, 17 | 42.5 ± 22.6 | 44.0 ± 13.9 | 48.2 ± 18.4 |
| Part I, Baseline (Month -3); n=27, 0, 0 | 2.9 ± 1.9 | NA ± NA | NA ± NA |
| Part I, Month 12; n=25, 20, 17 | 3.1 ± 2.2 | 2.6 ± 2.0 | 3.2 ± 2.2 |
| Part II, Baseline (Month -3); n=27, 0, 0 | 15.4 ± 5.7 | NA ± NA | NA ± NA |
| Part II, Month 12; n=25, 20, 17 | 12.2 ± 6.8 | 13.4 ± 5.7 | 14.3 ± 6.0 |
| Part III, Baseline (Month -3); n=27, 0, 0 | 24.4 ± 11.0 | NA ± NA | NA ± NA |
| Part III, Month 12; n=25, 20, 17 | 21.5 ± 13.2 | 21.2 ± 10.0 | 23.5 ± 11.5 |
| Part IV, Baseline (Month -3); n=27, 0, 0 | 9.4 ± 2.6 | NA ± NA | NA ± NA |
| Part IV, Month 12; n=25, 20, 17 | 5.7 ± 3.4 | 7.0 ± 2.5 | 7.2 ± 3.5 |
The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 (worst health state) to 1.00 (perfect health state).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 0.57 ± 0.26 | NA ± NA | NA ± NA |
| Month 12; n=25, 20, 17 | 0.59 ± 0.33 | 0.66 ± 0.36 | 0.51 ± 0.37 |
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 0.44 ± 0.20 | NA ± NA | NA ± NA |
| Month 12; n=25, 19, 17 | 0.63 ± 0.18 | 0.64 ± 0.19 | 0.64 ± 0.22 |
Total monthly costs include * Direct medical costs (inpatient care, outpatient care, and drug costs \[including Duodopa cost and cost of concomitant anti-PD medication\]). * Direct non-medical costs (nursing home, home help, personal assistance, informal care \[from family member or friend\] and transportation to inpatient, outpatient visits and nursing home). * Indirect costs (sick-leave and early retirement due to PD \[applied to individuals only up to the age of 65 since the main indirect cost item, early retirement due to disability, is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden\]). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
| SEK 2010 | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010 | 78418 ± 42028 | 75521 ± 73296 | 82177 ± 53728 | 78464 ± 56772 |
Drug costs include Duodopa cost and cost of concomitant anti-PD medication. Drug costs are a direct medical cost. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
| SEK 2010 | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Monthly Drug Costs Per Participant, SEK 2010 | 39382 ± 16733 | 34417 ± 10494 | 37679 ± 15196 | 37339 ± 14725 |
Direct medical costs consist of inpatient care, outpatient care (visits to physician, nurse, physiotherapist, occupational therapist, dietitian, speech therapist, counselor, and phone consultations). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
| SEK 2010 | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010 | 3825 ± 9394 | 4552 ± 11819 | 3607 ± 8648 | 4002 ± 10069 |
Direct non-medical costs include nursing home, home help, personal assistance, informal care (from family member or friend) and transportation to inpatient, outpatient visits and nursing home. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
| SEK 2010 | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Direct Monthly Non-medical Costs Per Participant, SEK 2010 | 19274 ± 26485 | 27439 ± 61656 | 25008 ± 42455 | 23398 ± 44698 |
Indirect costs consist of sick-leave and early retirement due to PD, are applied to individuals only up to the age of 65 since the main indirect cost item - early retirement due to disability - is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.
| SEK 2010 | Total |
|---|---|
| Month -3; n=15/37 | 17032 ± 20911 |
| Month 0; n=23/67 | 14109 ± 19823 |
| Month 1; n=23/67 | 14109 ± 19823 |
| Month 2; n=22/65 | 13896 ± 19746 |
| Month 3; n=23/65 | 14543 ± 19971 |
| Month 4; n=23/65 | 14543 ± 19971 |
| Month 5; n=22/65 | 13896 ± 19746 |
| Month 6; n=21/65 | 13250 ± 19498 |
| Month 7; n=24/65 | 15512 ± 20433 |
| Month 8; n=24/63 | 16005 ± 20566 |
| Month 9; n=22/62 | 14569 ± 19978 |
| Month 10; n=22/62 | 14569 ± 19978 |
| Month 11; n=22/62 | 14399 ± 19785 |
| Month 12; n=22/62 | 14399 ± 19785 |
| Month 13; n=22/62 | 14230 ± 19681 |
| Month 14; n=22/62 | 14569 ± 19978 |
| Month 15; n=22/61 | 14808 ± 20055 |
| Month 16; n=22/61 | 14808 ± 20055 |
| Month 17; n=22/61 | 14463 ± 19758 |
| Month 18; n=22/61 | 14463 ± 19758 |
| Month 19; n=22/60 | 14704 ± 19834 |
| Month 20; n=20/59 | 13529 ± 19411 |
| Month 21; n=20/58 | 13763 ± 19497 |
| Month 22; n=18/57 | 12530 ± 18980 |
| Month 23; n=18/57 | 12530 ± 18980 |
| Month 24; n=17/56 | 12003 ± 18727 |
| Month 25; n=16/54 | 12059 ± 18966 |
| Month 26; n=18/54 | 13615 ± 19637 |
| Month 27; n=16/53 | 12683 ± 19471 |
| Month 28; n=15/53 | 11890 ± 19106 |
| Month 29; n=16/53 | 12683 ± 19471 |
| Month 30; n=16/53 | 12683 ± 19471 |
| Month 31; n=15/50 | 12604 ± 19448 |
| Month 32; n=14/50 | 11763 ± 19055 |
| Month 33; n=14/50 | 11763 ± 19055 |
| Month 34; n=14/49 | 12003 ± 19176 |
| Month 35; n=14/49 | 12003 ± 19176 |
| Month 36; n=15/49 | 12432 ± 19137 |
The current stage of PD was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 2.7 ± 0.7 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 2.5 ± 0.7 | 2.7 ± 0.8 | 3.2 ± 0.8 |
| Month 3; n=24, 22, 18 | 2.3 ± 0.8 | 2.7 ± 0.8 | 3.0 ± 0.8 |
| Month 6; n=25, 22, 18 | 2.4 ± 0.8 | 2.6 ± 0.9 | 3.1 ± 0.8 |
| Month 9; n=25, 20, 17 | 2.4 ± 1.0 | 2.7 ± 0.7 | 3.1 ± 0.7 |
| Month 12; n=25, 20, 17 | 2.4 ± 0.8 | 2.8 ± 0.7 | 3.3 ± 0.8 |
| Month 18; n=24, 20, 17 | 2.4 ± 0.9 | 2.7 ± 0.7 | 3.4 ± 1.0 |
| Month 24; 23, 18, 15 | 2.5 ± 0.9 | 3.0 ± 0.9 | 3.2 ± 0.8 |
| Month 30; n=23, 17, 13 | 2.7 ± 1.1 | 2.9 ± 0.8 | 3.1 ± 0.9 |
| Month 36; n=21, 16, 12 | 2.7 ± 1.2 | 2.9 ± 0.6 | 3.3 ± 0.9 |
| Endpoint; n=27, 22, 18 | 2.7 ± 1.1 | 3.1 ± 0.8 | 3.4 ± 0.8 |
The best PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 2.2 ± 1.2 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 2.0 ± 0.9 | 2.5 ± 0.7 | 2.5 ± 0.7 |
| Month 3; n=24, 22, 18 | 2.0 ± 0.9 | 2.5 ± 0.6 | 2.6 ± 0.8 |
| Month 6; n=25, 22, 18 | 2.0 ± 0.8 | 2.5 ± 0.7 | 2.6 ± 0.9 |
| Month 9; 25, 20, 17 | 2.2 ± 1.1 | 2.5 ± 0.7 | 2.7 ± 0.7 |
| Month 12; n=25, 20, 17 | 2.2 ± 0.8 | 2.6 ± 0.9 | 2.9 ± 0.8 |
| Month 18; n=24, 20, 17 | 2.2 ± 0.9 | 2.5 ± 0.9 | 2.9 ± 0.9 |
| Month 24; n=23, 18, 15 | 2.3 ± 1.1 | 2.6 ± 1.0 | 2.9 ± 0.8 |
| Month 30; n=23, 17, 13 | 2.5 ± 1.2 | 2.6 ± 1.0 | 3.0 ± 0.9 |
| Month 36; n=21, 16, 12 | 2.5 ± 1.3 | 2.6 ± 0.6 | 3.0 ± 0.7 |
| Endpoint; n=27, 22, 18 | 2.6 ± 1.2 | 2.7 ± 0.7 | 3.1 ± 0.8 |
The worst PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 3.8 ± 1.0 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 3.6 ± 1.1 | 3.7 ± 0.9 | 4.0 ± 0.6 |
| Month 3; n=24, 22, 18 | 3.8 ± 1.2 | 3.7 ± 0.9 | 4.1 ± 0.7 |
| Month 6; n=25, 22, 18 | 3.7 ± 1.3 | 3.7 ± 1.1 | 4.0 ± 0.7 |
| Month 9; n=25, 20, 17 | 3.7 ± 1.2 | 3.8 ± 0.7 | 4.0 ± 0.5 |
| Month 12; n=25, 20, 17 | 3.6 ± 1.3 | 3.8 ± 0.8 | 4.2 ± 0.5 |
| Month 18; n=24, 20, 17 | 3.8 ± 1.3 | 3.9 ± 0.8 | 4.3 ± 0.6 |
| Month 24; n=23, 18, 15 | 3.9 ± 1.3 | 3.8 ± 0.8 | 4.4 ± 0.5 |
| Month 30; n=23, 17, 13 | 4.0 ± 1.1 | 4.0 ± 0.8 | 4.5 ± 0.7 |
| Month 36; n=21, 16, 12 | 3.9 ± 1.2 | 4.0 ± 0.6 | 4.6 ± 0.5 |
| Endpoint; n=27, 22, 18 | 3.9 ± 1.1 | 4.0 ± 0.7 | 4.5 ± 0.5 |
The Schwab and England scale was used to rate the subject's best "on" period during the past week by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%). "On" time is when PD symptoms are well controlled by the drug.
| percentage score on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 74.4 ± 15.8 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 80.4 ± 13.2 | 75.5 ± 14.4 | 74.4 ± 11.5 |
| Month 3; n=24, 22, 18 | 77.9 ± 14.4 | 75.9 ± 14.4 | 72.2 ± 15.2 |
| Month 6; n=25, 22, 18 | 75.2 ± 15.3 | 77.3 ± 11.6 | 72.2 ± 12.6 |
| Month 9; n=25, 20, 17 | 79.2 ± 13.5 | 76.5 ± 13.1 | 70.6 ± 13.0 |
| Month 12; n=25, 20, 17 | 77.2 ± 13.4 | 72.5 ± 15.9 | 71.8 ± 12.4 |
| Month 18; n=24, 20, 17 | 75.8 ± 12.8 | 74.0 ± 11.9 | 69.4 ± 14.3 |
| Month 24; n=23, 18, 15 | 72.2 ± 18.1 | 73.3 ± 14.6 | 68.0 ± 15.2 |
| Month 30; n=23, 17, 13 | 70.4 ± 18.7 | 71.8 ± 16.7 | 67.7 ± 17.9 |
| Month 36; n=21, 16, 12 | 66.7 ± 21.1 | 73.1 ± 13.0 | 64.2 ± 21.1 |
| Endpoint; n=27, 22, 18 | 68.9 ± 19.5 | 71.4 ± 13.2 | 62.2 ± 17.7 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score of 0 to 30, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 28.2 ± 2.2 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 27.8 ± 2.4 | 28.0 ± 2.2 | 28.2 ± 1.4 |
| Month 3; n=24, 22, 18 | 28.0 ± 2.9 | 27.2 ± 2.8 | 28.6 ± 1.9 |
| Month 6; n=25, 21, 18 | 28.1 ± 2.5 | 27.6 ± 1.9 | 28.1 ± 1.4 |
| Month 9; n=25, 20, 17 | 28.4 ± 2.3 | 27.6 ± 2.0 | 28.3 ± 2.1 |
| Month 12; n=25, 20, 17 | 27.9 ± 2.8 | 28.2 ± 1.7 | 28.2 ± 2.5 |
| Month 18; n=24, 19, 16 | 27.6 ± 2.7 | 28.5 ± 1.4 | 28.3 ± 2.3 |
| Month 24; n=23, 18, 15 | 27.7 ± 2.5 | 27.8 ± 2.0 | 28.0 ± 2.2 |
| Month 30; n=23, 17, 13 | 27.3 ± 3.9 | 26.4 ± 3.4 | 28.6 ± 2.0 |
| Month 36; n=21, 16, 12 | 27.2 ± 3.2 | 26.3 ± 4.0 | 27.9 ± 4.1 |
| Endpoint; n=27, 22, 17 | 27.1 ± 3.9 | 26.4 ± 3.8 | 27.3 ± 3.8 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The orientation subscale has a total possible score of 0 to 10, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 9.8 ± 0.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 9.6 ± 1.1 | 9.9 ± 0.4 | 9.8 ± 0.4 |
| Month 3; n=24, 22, 18 | 9.4 ± 1.2 | 9.5 ± 1.1 | 9.6 ± 0.6 |
| Month 6; n=25, 21, 18 | 9.7 ± 0.7 | 9.6 ± 0.9 | 9.7 ± 0.6 |
| Month 9; n=25, 20, 17 | 9.8 ± 0.5 | 9.9 ± 0.4 | 9.6 ± 1.0 |
| Month 12; n=25, 20, 17 | 9.6 ± 1.1 | 9.8 ± 0.6 | 9.7 ± 1.0 |
| Month 18; n=24, 19, 16 | 9.7 ± 0.7 | 9.7 ± 0.6 | 9.9 ± 0.3 |
| Month 24; n=23, 18, 15 | 9.7 ± 0.6 | 9.8 ± 0.5 | 9.9 ± 0.4 |
| Month 30; n=23, 17, 13 | 9.4 ± 1.2 | 8.9 ± 1.9 | 9.8 ± 0.6 |
| Month 36; n=21, 16, 12 | 9.6 ± 1.0 | 9.3 ± 1.2 | 9.1 ± 2.2 |
| Endpoint; n=27, 22, 17 | 9.5 ± 1.1 | 8.9 ± 1.6 | 9.2 ± 1.8 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Registration subscale a total possible score of 0 to 3, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 3.0 ± 0.0 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 3.0 ± 0.2 | 3.0 ± 0.2 | 3.0 ± 0.0 |
| Month 3; n=24, 22, 18 | 3.0 ± 0.0 | 3.0 ± 0.2 | 3.0 ± 0.0 |
| Month 6; n=25, 21, 18 | 3.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.0 |
| Month 9; n=25, 20, 17 | 3.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.0 |
| Month 12; n=25, 20, 17 | 3.0 ± 0.2 | 3.0 ± 0.0 | 3.0 ± 0.0 |
| Month 18; n=24, 19, 16 | 3.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.0 |
| Month 24; n=23, 18, 15 | 3.0 ± 0.2 | 3.0 ± 0.0 | 3.0 ± 0.0 |
| Month 30; n=23, 17, 13 | 3.0 ± 0.0 | 2.9 ± 0.2 | 3.0 ± 0.0 |
| Month 36; n=21, 16, 12 | 3.0 ± 0.0 | 3.0 ± 0.0 | 2.9 ± 0.3 |
| Endpoint; n=27, 22, 17 | 3.0 ± 0.0 | 3.0 ± 0.0 | 2.9 ± 0.2 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Attention and Calculation subscale results in a total possible score of 0 to 5, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 4.9 ± 0.4 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 4.6 ± 0.9 | 4.4 ± 1.4 | 4.6 ± 0.7 |
| Month 3; n=24, 22, 18 | 4.6 ± 0.9 | 4.3 ± 1.3 | 4.7 ± 0.8 |
| Month 6; n=25, 21, 18 | 4.6 ± 1.0 | 4.5 ± 0.8 | 4.7 ± 0.6 |
| Month 9; n=25, 20, 17 | 4.7 ± 0.6 | 4.3 ± 1.0 | 4.8 ± 0.5 |
| Month 12; n=25, 20, 17 | 4.7 ± 0.6 | 4.7 ± 0.7 | 4.6 ± 0.7 |
| Month 18; n=24, 19, 16 | 4.5 ± 1.1 | 4.7 ± 0.8 | 4.5 ± 1.1 |
| Month 24; n=23, 18, 15 | 4.6 ± 0.7 | 4.6 ± 0.6 | 4.3 ± 1.2 |
| Month 30; n=23, 17, 13 | 4.6 ± 1.0 | 4.1 ± 1.2 | 4.8 ± 0.4 |
| Month 36; n=21, 16, 12 | 4.2 ± 1.5 | 3.7 ± 1.9 | 4.8 ± 0.6 |
| Endpoint; n=27, 22, 17 | 4.2 ± 1.5 | 4.0 ± 1.7 | 4.4 ± 0.9 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Recall subscale results in a total possible score of 0 to 3, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 2.2 ± 0.9 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 2.2 ± 1.0 | 2.1 ± 0.8 | 2.3 ± 0.8 |
| Month 3; n=24, 22, 18 | 2.5 ± 0.9 | 2.1 ± 0.9 | 2.5 ± 0.6 |
| Month 6; n=25, 21, 18 | 2.5 ± 0.8 | 2.4 ± 0.8 | 2.3 ± 0.8 |
| Month 9; n=25, 20, 17 | 2.5 ± 0.8 | 2.2 ± 0.8 | 2.5 ± 0.9 |
| Month 12; n=25, 20, 17 | 2.5 ± 0.9 | 2.5 ± 0.8 | 2.6 ± 0.9 |
| Month 18; n=24, 19, 16 | 2.3 ± 0.7 | 2.5 ± 0.5 | 2.6 ± 0.9 |
| Month 24; n=23, 18, 15 | 2.4 ± 0.8 | 2.3 ± 0.8 | 2.5 ± 0.9 |
| Month 30; n=23, 17, 13 | 2.5 ± 0.9 | 2.5 ± 0.6 | 2.6 ± 0.8 |
| Month 36; n=21, 16, 12 | 2.2 ± 0.9 | 2.4 ± 0.7 | 2.8 ± 0.5 |
| Endpoint; n=27, 22, 17 | 2.2 ± 0.9 | 2.5 ± 0.7 | 2.5 ± 0.8 |
The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Language subscale results in a total possible score of 0 to 9, with higher scores indicating better function.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 8.3 ± 1.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 8.5 ± 0.9 | 8.6 ± 0.5 | 8.5 ± 0.7 |
| Month 3; n=24, 22, 18 | 8.4 ± 0.7 | 8.3 ± 0.9 | 8.7 ± 0.5 |
| Month 6; n=25, 21, 18 | 8.3 ± 0.9 | 8.1 ± 1.3 | 8.3 ± 0.7 |
| Month 9; n=25, 20, 17 | 8.4 ± 1.0 | 8.2 ± 0.9 | 8.4 ± 0.7 |
| Month 12; n=25, 20, 17 | 8.2 ± 1.3 | 8.3 ± 0.7 | 8.2 ± 0.8 |
| Month 18; n=24, 19, 16 | 8.2 ± 1.1 | 8.6 ± 0.6 | 8.3 ± 0.9 |
| Month 24; n=23, 18, 15 | 8.0 ± 1.4 | 8.1 ± 0.9 | 8.3 ± 0.8 |
| Month 30; n=23, 17, 13 | 7.9 ± 1.4 | 8.0 ± 0.9 | 8.5 ± 1.0 |
| Month 36; n=21, 16, 12 | 8.3 ± 0.9 | 7.9 ± 1.3 | 8.4 ± 1.0 |
| Endpoint; n=27, 22, 17 | 8.3 ± 0.9 | 7.9 ± 1.3 | 8.4 ± 1.0 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Total score ranges from 0 (no depression) to 60 (severely depressed).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 10.3 ± 5.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 9.0 ± 5.3 | 7.8 ± 5.2 | 8.8 ± 5.8 |
| Month 3; n=24, 22, 17 | 10.2 ± 6.3 | 8.1 ± 4.9 | 8.4 ± 5.8 |
| Month 6; n=25, 21, 17 | 10.5 ± 6.9 | 8.4 ± 3.8 | 8.5 ± 5.3 |
| Month 9; n=25, 20, 17 | 8.8 ± 4.9 | 8.0 ± 3.4 | 9.9 ± 6.5 |
| Month 12; n=25, 20, 17 | 8.6 ± 5.7 | 8.8 ± 5.2 | 9.5 ± 7.3 |
| Month 18; n=24, 19, 16 | 10.6 ± 6.2 | 8.1 ± 4.5 | 9.1 ± 7.1 |
| Month 24; n=23, 18, 15 | 10.1 ± 5.6 | 9.7 ± 5.5 | 11.1 ± 7.4 |
| Month 30; n=22, 17, 13 | 12.0 ± 5.9 | 10.6 ± 4.6 | 9.0 ± 5.0 |
| Month 36; n=21, 16, 12 | 12.2 ± 7.3 | 9.1 ± 4.5 | 10.4 ± 9.4 |
| Endpoint; n=26, 22, 17 | 11.6 ± 7.0 | 9.0 ± 4.9 | 12.3 ± 9.1 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reported Sadness scores rate depressed mood, regardless of whether it is reflected in appearance or not, and includes low spirits, despondency or the feeling of being beyond help and without hope.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.9 ± 0.8 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 0.6 ± 0.7 | 0.8 ± 1.2 | 0.8 ± 1.0 |
| Month 3; n=24, 22, 17 | 0.9 ± 1.0 | 0.6 ± 0.8 | 0.5 ± 0.6 |
| Month 6; n=25, 21, 17 | 1.1 ± 1.1 | 0.8 ± 0.6 | 0.5 ± 0.7 |
| Month 9; n=25, 20, 17 | 0.9 ± 0.7 | 0.9 ± 0.8 | 1.1 ± 1.4 |
| Month 12; n=25, 20, 17 | 0.6 ± 0.7 | 1.1 ± 0.9 | 0.8 ± 1.0 |
| Month 18; n=24, 19, 16 | 1.0 ± 1.0 | 0.7 ± 0.7 | 0.8 ± 0.8 |
| Month 24; n=23, 18, 15 | 1.0 ± 1.0 | 0.9 ± 0.9 | 0.8 ± 0.7 |
| Month 30; n=23, 17, 13 | 1.2 ± 0.9 | 0.9 ± 0.8 | 0.9 ± 1.0 |
| Month 36; n=21, 16, 12 | 1.1 ± 1.2 | 0.9 ± 0.9 | 1.1 ± 1.1 |
| Endpoint; n=27, 22, 17 | 1.2 ± 1.2 | 0.8 ± 0.9 | 1.0 ± 1.0 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Apparent sadness scores rate despondency, gloom and despair (more than just ordinary transient low spirits), reflected in speech, facial expression, and posture.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.7 ± 0.8 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 0.4 ± 0.8 | 0.5 ± 0.9 | 0.8 ± 0.7 |
| Month 3; n=24, 22, 17 | 0.8 ± 0.9 | 0.6 ± 0.8 | 0.5 ± 0.7 |
| Month 6; n=25, 21, 17 | 1.0 ± 1.1 | 0.6 ± 0.5 | 0.5 ± 0.6 |
| Month 9; n=25, 20, 17 | 0.9 ± 0.8 | 0.7 ± 0.7 | 0.9 ± 1.0 |
| Month 12; n=25, 20, 17 | 0.4 ± 0.5 | 0.9 ± 1.0 | 0.8 ± 0.8 |
| Month 18; n=24, 19, 16 | 0.8 ± 0.9 | 0.6 ± 0.7 | 0.8 ± 0.9 |
| Month 24; n=23, 18, 15 | 1.0 ± 1.2 | 0.6 ± 0.7 | 0.7 ± 0.6 |
| Month 30; n=23, 17, 13 | 1.2 ± 1.0 | 1.0 ± 0.9 | 0.6 ± 0.7 |
| Month 36; n=21, 16, 12 | 1.1 ± 1.2 | 0.8 ± 0.9 | 1.3 ± 1.4 |
| Endpoint; n=27, 22, 17 | 1.1 ± 1.2 | 0.8 ± 1.0 | 1.0 ± 1.2 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inner Tension scores rate feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 1.3 ± 1.3 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 1.3 ± 1.1 | 1.0 ± 1.0 | 0.9 ± 1.0 |
| Month 3; n=24, 22, 17 | 1.5 ± 1.3 | 0.8 ± 1.0 | 0.9 ± 1.0 |
| Month 6; n=25, 21, 17 | 1.1 ± 1.1 | 0.9 ± 1.0 | 1.2 ± 1.1 |
| Month 9; n=25, 20, 17 | 0.9 ± 1.2 | 0.6 ± 0.8 | 0.9 ± 1.1 |
| Month 12; n=25, 20, 17 | 1.1 ± 1.1 | 0.7 ± 0.9 | 1.5 ± 1.0 |
| Month 18; n=24, 19, 16 | 1.2 ± 1.1 | 0.7 ± 0.9 | 0.8 ± 1.0 |
| Month 24; n=23, 18, 15 | 1.0 ± 1.1 | 0.8 ± 1.1 | 1.3 ± 1.3 |
| Month 30; n=23, 17, 13 | 1.1 ± 1.1 | 1.1 ± 1.2 | 1.5 ± 1.1 |
| Month 36; n=21, 16, 12 | 1.7 ± 1.2 | 0.6 ± 0.8 | 1.3 ± 1.2 |
| Endpoint; n=27, 22, 17 | 1.6 ± 1.1 | 0.6 ± 0.8 | 1.5 ± 1.3 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Sleep scores rate the experience of reduced duration or depth of sleep compared to the participant's own normal pattern when well.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 2.5 ± 1.7 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 1.9 ± 1.6 | 1.5 ± 1.6 | 1.7 ± 1.8 |
| Month 3; n=24, 22, 17 | 2.0 ± 1.4 | 1.8 ± 1.6 | 1.2 ± 1.2 |
| Month 6; n=25, 21, 17 | 1.8 ± 1.8 | 1.7 ± 1.5 | 1.5 ± 1.7 |
| Month 9; n=25, 20, 17 | 1.8 ± 1.5 | 1.9 ± 1.3 | 1.4 ± 1.5 |
| Month 12; n=25, 20, 17 | 1.8 ± 1.5 | 1.5 ± 1.5 | 1.2 ± 1.4 |
| Month 18; n=24, 19, 16 | 1.7 ± 1.3 | 1.5 ± 1.5 | 1.7 ± 1.4 |
| Month 24; n=23, 18, 15 | 1.6 ± 1.3 | 1.8 ± 1.9 | 1.5 ± 1.7 |
| Month 30; n=23, 17, 13 | 2.3 ± 1.7 | 1.9 ± 1.9 | 0.9 ± 1.0 |
| Month 36; n=21, 16, 12 | 1.9 ± 1.7 | 1.2 ± 1.4 | 1.2 ± 1.5 |
| Endpoint; n=27, 22, 17 | 1.6 ± 1.7 | 1.4 ± 1.5 | 2.0 ± 2.2 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Appetite scores rate the feeling of a loss of appetite compared with when-well. Rate by loss of desire for food or the need to force oneself to eat.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.8 ± 1.1 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 0.6 ± 0.8 | 0.2 ± 0.5 | 0.3 ± 0.8 |
| Month 3; n=24, 22, 17 | 0.7 ± 1.0 | 0.4 ± 0.8 | 0.4 ± 1.0 |
| Month 6; n=25, 21, 17 | 0.8 ± 1.1 | 0.3 ± 0.7 | 0.5 ± 1.2 |
| Month 9; n=25, 20, 17 | 0.5 ± 0.8 | 0.4 ± 0.6 | 0.8 ± 1.4 |
| Month 12; n=25, 20, 17 | 0.5 ± 0.8 | 0.6 ± 0.8 | 0.7 ± 1.2 |
| Month 18; n=24, 19, 16 | 0.5 ± 0.8 | 0.3 ± 0.7 | 0.4 ± 0.9 |
| Month 24; n=23, 18, 15 | 0.7 ± 1.2 | 0.5 ± 0.8 | 0.7 ± 1.1 |
| Month 30; n=23, 17, 13 | 1.0 ± 1.2 | 0.4 ± 0.6 | 0.5 ± 1.1 |
| Month 36; n=21, 16, 12 | 0.9 ± 1.2 | 0.4 ± 0.7 | 1.1 ± 1.4 |
| Endpoint; n=27, 22, 17 | 0.9 ± 1.2 | 0.3 ± 0.6 | 1.1 ± 1.3 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Concentration Difficulties scores rate difficulties in collecting one's thoughts mounting to an incapacitating lack of concentration.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 1.0 ± 1.0 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 1.0 ± 1.2 | 1.5 ± 1.3 | 0.9 ± 1.2 |
| Month 3; n=24, 22, 17 | 0.9 ± 1.1 | 1.3 ± 0.9 | 1.2 ± 1.2 |
| Month 6; n=25, 21, 17 | 1.2 ± 1.2 | 1.4 ± 0.9 | 1.2 ± 1.1 |
| Month 9; n=25, 20, 17 | 1.0 ± 1.2 | 1.1 ± 1.1 | 1.3 ± 1.2 |
| Month 12; n=25, 20, 17 | 0.9 ± 1.2 | 1.2 ± 1.1 | 1.4 ± 1.3 |
| Month 18; n=24, 19, 16 | 1.5 ± 1.4 | 1.4 ± 1.0 | 1.4 ± 1.3 |
| Month 24; n=23, 18, 15 | 1.5 ± 1.3 | 1.7 ± 1.5 | 1.7 ± 1.4 |
| Month 30; n=23, 17, 13 | 1.5 ± 1.7 | 2.1 ± 1.1 | 1.5 ± 1.5 |
| Month 36; n=21, 16, 12 | 1.6 ± 1.3 | 1.9 ± 1.3 | 1.2 ± 1.7 |
| Endpoint; n=27, 22, 17 | 1.6 ± 1.5 | 1.7 ± 1.3 | 1.6 ± 1.7 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Lassitude scores rate difficulty in getting started or slowness in initiating and performing everyday activities.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 1.3 ± 1.4 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 1.4 ± 1.3 | 1.4 ± 1.2 | 1.7 ± 1.5 |
| Month 3; n=24, 22, 17 | 1.7 ± 1.3 | 1.5 ± 1.0 | 2.0 ± 1.6 |
| Month 6; n=25, 21, 17 | 1.5 ± 1.3 | 1.5 ± 1.2 | 1.3 ± 1.5 |
| Month 9; n=25, 20, 17 | 1.3 ± 1.2 | 1.5 ± 1.2 | 1.7 ± 1.2 |
| Month 12; n=25, 20, 17 | 1.6 ± 1.4 | 1.6 ± 1.3 | 1.4 ± 1.6 |
| Month 18; n=24, 19, 16 | 1.8 ± 1.6 | 1.4 ± 1.2 | 1.6 ± 1.1 |
| Month 24; n=23, 18, 15 | 1.7 ± 1.5 | 1.9 ± 1.1 | 1.7 ± 1.4 |
| Month 30; n=23, 17, 13 | 2.0 ± 1.4 | 1.7 ± 1.3 | 1.3 ± 1.1 |
| Month 36; n=21, 16, 12 | 1.9 ± 1.5 | 1.8 ± 1.4 | 1.7 ± 1.4 |
| Endpoint; n=27, 22, 17 | 1.8 ± 1.5 | 1.7 ± 1.4 | 1.7 ± 1.4 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inability to Feel scores rate the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is reduced.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.5 ± 0.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 0.4 ± 0.7 | 0.2 ± 0.5 | 0.8 ± 0.8 |
| Month 3; n=24, 22, 17 | 0.6 ± 0.9 | 0.6 ± 0.9 | 0.6 ± 1.1 |
| Month 6; n=25, 21, 17 | 0.6 ± 1.0 | 0.4 ± 0.7 | 0.8 ± 1.3 |
| Month 9; n=25, 20, 17 | 0.5 ± 0.8 | 0.6 ± 0.6 | 0.7 ± 1.1 |
| Month 12; n=25, 20, 17 | 0.6 ± 0.8 | 0.4 ± 0.6 | 0.5 ± 1.1 |
| Month 18; n=24, 19, 16 | 0.5 ± 0.8 | 0.5 ± 0.6 | 0.8 ± 1.0 |
| Month 24; n=23, 18, 15 | 0.5 ± 0.7 | 0.6 ± 0.7 | 1.1 ± 1.4 |
| Month 30; n=23, 17, 13 | 0.4 ± 0.6 | 0.7 ± 0.7 | 0.7 ± 0.9 |
| Month 36; n=21, 16, 12 | 0.6 ± 0.8 | 0.5 ± 0.7 | 0.7 ± 1.4 |
| Endpoint; n=27, 22, 17 | 0.6 ± 0.8 | 0.6 ± 0.7 | 0.9 ± 1.4 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Pessimistic Thoughts scores rate thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.9 ± 1.1 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 1.0 ± 0.8 | 0.5 ± 0.9 | 0.6 ± 0.8 |
| Month 3; n=24, 22, 17 | 0.7 ± 0.9 | 0.5 ± 1.0 | 0.8 ± 1.0 |
| Month 6; n=25, 21, 17 | 0.9 ± 0.9 | 0.6 ± 0.7 | 0.6 ± 0.9 |
| Month 9; n=25, 20, 17 | 0.8 ± 0.8 | 0.5 ± 0.5 | 0.9 ± 1.0 |
| Month 12; n=25, 20, 17 | 0.9 ± 0.8 | 0.8 ± 0.8 | 1.0 ± 0.9 |
| Month 18; n=24, 19, 16 | 1.0 ± 0.8 | 0.7 ± 0.9 | 0.8 ± 0.8 |
| Month 24; n=23, 18, 15 | 1.0 ± 1.0 | 0.7 ± 0.8 | 1.1 ± 0.9 |
| Month 30; n=22, 17, 13 | 1.2 ± 0.9 | 0.7 ± 0.7 | 0.9 ± 0.8 |
| Month 36; n=21, 16, 12 | 1.0 ± 1.0 | 0.9 ± 0.8 | 1.0 ± 1.1 |
| Endpoint; n=26, 22, 17 | 1.2 ± 1.1 | 0.9 ± 0.8 | 1.1 ± 1.2 |
MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Suicidal Thoughts scores rate the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=26, 0, 0 | 0.4 ± 0.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 0.5 ± 1.0 | 0.2 ± 0.6 | 0.3 ± 0.7 |
| Month 3; n=24, 22, 17 | 0.5 ± 1.1 | 0.0 ± 0.2 | 0.4 ± 0.6 |
| Month 6; n=25, 21, 17 | 0.5 ± 1.0 | 0.1 ± 0.4 | 0.2 ± 0.4 |
| Month 9; n=25, 20, 17 | 0.3 ± 0.7 | 0.0 ± 0.0 | 0.2 ± 0.4 |
| Month 12; n=25, 20, 17 | 0.3 ± 0.7 | 0.3 ± 0.4 | 0.2 ± 0.7 |
| Month 18; n=24, 19, 16 | 0.5 ± 0.9 | 0.3 ± 0.7 | 0.2 ± 0.4 |
| Month 24; n=23, 18, 15 | 0.1 ± 0.3 | 0.2 ± 0.5 | 0.4 ± 0.8 |
| Month 30; n=23, 17, 13 | 0.4 ± 0.8 | 0.1 ± 0.3 | 0.2 ± 0.4 |
| Month 36; n=21, 16, 12 | 0.5 ± 1.0 | 0.1 ± 0.3 | 0.1 ± 0.3 |
| Endpoint; n=27, 22, 17 | 0.4 ± 0.9 | 0.2 ± 0.4 | 0.4 ± 0.8 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible, which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 33.6 ± 10.8 | NA ± NA | NA ± NA |
| Month 0; n=27, 20, 17 | 27.1 ± 11.8 | 30.3 ± 10.7 | 36.6 ± 15.4 |
| Month 3; n=22, 20, 18 | 24.5 ± 10.1 | 30.0 ± 15.6 | 34.0 ± 15.2 |
| Month 6; n=24, 20, 17 | 27.9 ± 10.6 | 33.4 ± 16.2 | 35.5 ± 16.5 |
| Month 9; n=23, 20, 16 | 25.9 ± 10.6 | 30.9 ± 12.1 | 35.1 ± 15.9 |
| Month 12; n=23, 19, 17 | 28.8 ± 12.8 | 33.2 ± 15.5 | 38.3 ± 19.3 |
| Month 18; n=22, 18, 16 | 28.2 ± 12.2 | 30.4 ± 15.7 | 34.1 ± 17.0 |
| Month 24; n=21, 17, 14 | 30.3 ± 12.4 | 36.2 ± 14.6 | 33.6 ± 13.6 |
| Month 30; n=21, 16, 12 | 33.5 ± 13.1 | 34.8 ± 16.2 | 34.4 ± 17.4 |
| Month 36; n=20, 15, 11 | 36.8 ± 15.1 | 31.5 ± 11.5 | 39.2 ± 18.0 |
| Endpoint; n=25, 21, 17 | 36.2 ± 14.1 | 34.0 ± 13.6 | 40.3 ± 17.5 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 55.7 ± 20.5 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 38.8 ± 20.1 | 43.9 ± 21.7 | 53.3 ± 22.6 |
| Month 3; n=23, 20, 18 | 36.0 ± 17.6 | 40.6 ± 22.8 | 50.6 ± 24.2 |
| Month 6; n=25, 21, 18 | 39.5 ± 18.9 | 43.5 ± 23.5 | 54.7 ± 24.4 |
| Month 9; n=24, 20, 17 | 40.2 ± 15.6 | 41.9 ± 21.7 | 52.8 ± 23.0 |
| Month 12; n=25, 20, 17 | 41.0 ± 18.3 | 45.3 ± 24.2 | 54.4 ± 32.1 |
| Month 18; n=24, 18, 16 | 40.9 ± 16.2 | 41.1 ± 25.6 | 54.7 ± 29.2 |
| Month 24; n=21, 17, 15 | 46.0 ± 22.2 | 47.1 ± 21.5 | 49.5 ± 23.0 |
| Month 30; n=22, 17, 12 | 50.9 ± 21.5 | 42.1 ± 21.5 | 53.3 ± 24.8 |
| Month 36; n=21, 15, 11 | 57.3 ± 20.8 | 43.0 ± 21.6 | 61.1 ± 28.1 |
| Endpoint; n=26, 21, 17 | 55.6 ± 20.7 | 50.2 ± 22.2 | 61.6 ± 25.0 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 38.7 ± 21.5 | NA ± NA | NA ± NA |
| Month 0; n=27, 20, 18 | 32.1 ± 19.0 | 40.8 ± 19.1 | 46.5 ± 26.5 |
| Month 3; n=24, 22, 18 | 26.9 ± 16.6 | 42.8 ± 21.8 | 41.7 ± 22.2 |
| Month 6; n=25, 21, 18 | 31.8 ± 18.9 | 43.7 ± 23.2 | 42.1 ± 22.5 |
| Month 9; n=25, 20, 17 | 29.8 ± 19.2 | 37.5 ± 18.4 | 42.2 ± 21.3 |
| Month 12; n=25, 20, 17 | 34.7 ± 20.8 | 42.1 ± 20.7 | 45.6 ± 26.5 |
| Month 18; n=24, 20, 16 | 33.2 ± 20.1 | 41.9 ± 22.9 | 45.8 ± 24.6 |
| Month 24; n=21, 17, 15 | 37.1 ± 22.1 | 48.3 ± 20.8 | 41.9 ± 24.1 |
| Month 30; n=22, 17, 12 | 38.8 ± 23.8 | 48.5 ± 19.7 | 46.5 ± 28.2 |
| Month 36; n=21, 15, 11 | 45.4 ± 25.1 | 47.5 ± 18.4 | 54.5 ± 29.3 |
| Endpoint; n=26, 22, 17 | 43.4 ± 23.3 | 48.3 ± 18.2 | 53.4 ± 24.5 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 35.3 ± 19.3 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 30.9 ± 17.3 | 27.1 ± 19.3 | 37.7 ± 17.0 |
| Month 3; n=23, 22, 18 | 24.8 ± 19.5 | 27.5 ± 19.6 | 35.4 ± 21.5 |
| Month 6; n=25, 20, 18 | 31.3 ± 15.2 | 33.3 ± 18.6 | 35.9 ± 20.0 |
| Month 9; n=25, 20, 17 | 33.0 ± 18.0 | 32.1 ± 17.0 | 34.8 ± 18.6 |
| Month 12; n=25, 20, 17 | 29.0 ± 17.8 | 34.8 ± 20.8 | 38.0 ± 23.6 |
| Month 18; n=24, 20, 16 | 32.1 ± 16.2 | 30.2 ± 19.5 | 32.6 ± 22.5 |
| Month 24; n=21, 17, 15 | 31.9 ± 17.3 | 37.7 ± 19.0 | 33.1 ± 16.6 |
| Month 30; n=22, 16, 12 | 33.9 ± 16.8 | 33.3 ± 25.2 | 31.3 ± 18.2 |
| Month 36; n=21, 15, 11 | 39.7 ± 18.5 | 30.0 ± 21.0 | 38.6 ± 19.4 |
| Endpoint; n=26, 22, 17 | 39.4 ± 17.8 | 31.1 ± 24.4 | 39.7 ± 21.5 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 24.8 ± 15.4 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 16.2 ± 16.8 | 16.5 ± 18.5 | 22.9 ± 23.0 |
| Month 3; n=24, 22, 18 | 16.1 ± 15.0 | 18.8 ± 23.8 | 19.8 ± 17.4 |
| Month 6; n=25, 21, 18 | 20.8 ± 16.2 | 19.0 ± 19.3 | 23.6 ± 24.4 |
| Month 9; n=25, 20, 17 | 15.5 ± 15.7 | 12.8 ± 15.1 | 24.6 ± 23.6 |
| Month 12; n=25, 19, 17 | 17.8 ± 17.0 | 19.4 ± 19.9 | 25.4 ± 25.5 |
| Month 18; n=24, 20, 16 | 15.6 ± 17.5 | 13.8 ± 15.1 | 18.8 ± 22.0 |
| Month 24; n=21, 17, 15 | 15.8 ± 12.4 | 23.5 ± 19.2 | 15.4 ± 14.5 |
| Month 30; n=21, 17, 12 | 16.4 ± 18.6 | 14.0 ± 23.6 | 18.2 ± 21.4 |
| Month 36; n=21, 15, 11 | 20.5 ± 19.1 | 12.9 ± 20.0 | 24.4 ± 19.3 |
| Endpoint; n=26, 22, 17 | 19.5 ± 18.8 | 15.6 ± 20.3 | 25.0 ± 23.8 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27,0,0 | 8.3 ± 15.9 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 17 | 10.3 ± 18.2 | 12.9 ± 14.5 | 22.1 ± 19.1 |
| Month 3; n=24, 22, 18 | 10.8 ± 15.2 | 12.5 ± 18.7 | 16.7 ± 19.6 |
| Month 6; n=25, 21, 17 | 12.7 ± 18.0 | 13.1 ± 14.1 | 24.3 ± 21.5 |
| Month 9; n=24, 20, 16 | 10.2 ± 16.3 | 13.8 ± 14.9 | 25.5 ± 18.1 |
| Month 12; n=23, 20, 17 | 12.1 ± 19.5 | 19.6 ± 19.4 | 28.4 ± 22.6 |
| Month 18; n=22, 20, 16 | 12.7 ± 15.6 | 17.9 ± 19.4 | 18.8 ± 18.4 |
| Month 24; n=21, 17, 14 | 15.7 ± 18.5 | 20.6 ± 18.7 | 21.7 ± 15.7 |
| Month 30; n=22, 17, 12 | 18.2 ± 24.8 | 16.2 ± 20.3 | 18.8 ± 22.8 |
| Month 36; n=21, 15, 11 | 18.3 ± 21.0 | 11.7 ± 13.3 | 29.5 ± 26.7 |
| Endpoint; n=26, 22, 17 | 21.8 ± 25.3 | 14.4 ± 18.9 | 27.9 ± 25.3 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 30.6 ± 15.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 22.5 ± 13.7 | 33.0 ± 16.6 | 33.7 ± 16.9 |
| Month 3; n=24, 22, 18 | 24.2 ± 17.7 | 36.6 ± 18.5 | 32.3 ± 20.4 |
| Month 6; n=24, 21, 18 | 25.5 ± 13.7 | 37.8 ± 18.3 | 30.6 ± 16.9 |
| Month 9; n=25, 20, 17 | 21.5 ± 14.9 | 35.6 ± 20.0 | 31.6 ± 19.2 |
| Month 12; n=25, 20, 17 | 26.8 ± 20.8 | 33.1 ± 19.7 | 33.8 ± 23.2 |
| Month 18; n=24, 20, 16 | 28.6 ± 20.2 | 31.3 ± 22.1 | 30.1 ± 23.4 |
| Month 24; n=21, 17, 15 | 24.7 ± 14.7 | 41.9 ± 16.8 | 27.5 ± 19.0 |
| Month 30; n=22, 16, 12 | 31.5 ± 18.6 | 45.7 ± 23.7 | 30.7 ± 24.6 |
| Month 36; n=20, 15, 11 | 34.1 ± 19.4 | 42.1 ± 16.6 | 30.7 ± 19.7 |
| Endpoint; n=25, 22, 17 | 31.5 ± 19.8 | 39.2 ± 20.2 | 34.9 ± 19.5 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 32.4 ± 21.6 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 24.1 ± 18.7 | 27.3 ± 14.6 | 35.2 ± 18.4 |
| Month 3; n=24, 22, 18 | 24.7 ± 20.3 | 32.2 ± 22.2 | 31.9 ± 19.9 |
| Month 6; n=24, 21, 18 | 24.0 ± 17.1 | 32.5 ± 22.0 | 33.8 ± 19.3 |
| Month 9; n=25, 20, 17 | 25.3 ± 23.3 | 31.7 ± 17.2 | 28.9 ± 21.3 |
| Month 12; n=25, 20, 17 | 29.7 ± 20.1 | 34.2 ± 18.3 | 33.8 ± 16.0 |
| Month 18; n=24, 20, 16 | 31.6 ± 21.8 | 32.1 ± 19.0 | 29.7 ± 20.4 |
| Month 24; n=21, 17, 15 | 28.2 ± 19.6 | 34.8 ± 18.2 | 30.6 ± 19.1 |
| Month 30; n=22, 17, 12 | 33.7 ± 22.6 | 37.7 ± 18.4 | 41.7 ± 26.6 |
| Month 36; n=21, 15, 11 | 33.7 ± 20.7 | 33.3 ± 13.0 | 37.9 ± 19.1 |
| Endpoint; n=26, 22, 17 | 34.0 ± 20.9 | 33.0 ± 15.5 | 40.2 ± 18.7 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Baseline (Month -3); n=27, 0, 0 | 42.6 ± 19.8 | NA ± NA | NA ± NA |
| Month 0; n=27, 22, 18 | 41.7 ± 18.3 | 40.2 ± 17.6 | 43.1 ± 24.8 |
| Month 3; n=24, 22, 18 | 38.5 ± 21.7 | 39.8 ± 20.7 | 44.0 ± 21.4 |
| Month 6; n=24, 21, 18 | 38.9 ± 22.1 | 42.1 ± 20.5 | 39.4 ± 23.2 |
| Month 9; n=25, 20, 17 | 36.3 ± 18.8 | 42.1 ± 23.6 | 41.2 ± 24.7 |
| Month 12; n=25, 20, 17 | 39.3 ± 21.0 | 34.6 ± 20.1 | 46.6 ± 27.6 |
| Month 18; n=24, 20, 16 | 38.5 ± 23.5 | 37.1 ± 20.7 | 42.7 ± 24.5 |
| Month 24; n=21, 17, 15 | 42.9 ± 24.2 | 35.3 ± 25.8 | 38.9 ± 23.7 |
| Month 30; n=22, 17, 12 | 42.8 ± 23.3 | 39.2 ± 24.8 | 34.7 ± 27.3 |
| Month 36; n=21, 15, 11 | 42.9 ± 17.9 | 31.7 ± 15.8 | 37.1 ± 20.2 |
| Endpoint; n=26, 22, 17 | 42.6 ± 19.2 | 36.7 ± 20.5 | 39.7 ± 24.6 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Walking scores ranged from 1 (worst) to 5 (best).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 2.7 ± 1.2 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 3.1 ± 0.9 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 3.3 ± 1.4 | 3.2 ± 1.1 | 3.4 ± 1.0 |
| Day, Month 0; n=19, 20, 15 | 3.7 ± 1.1 | 3.7 ± 0.8 | 3.3 ± 1.0 |
| Morning, Month 3; n=19, 19, 13 | 3.5 ± 1.1 | 3.0 ± 1.1 | 3.1 ± 1.0 |
| Day, Month 3; n=19, 19, 13 | 3.7 ± 0.8 | 3.6 ± 1.0 | 3.3 ± 0.9 |
| Morning, Month 6; n=16, 19, 11 | 3.5 ± 1.2 | 3.2 ± 1.1 | 3.3 ± 1.1 |
| Day, Month 6; n=16, 19, 11 | 4.0 ± 0.7 | 3.7 ± 0.9 | 3.4 ± 0.9 |
| Morning, Month 9; n=16, 17, 9 | 3.6 ± 1.0 | 3.3 ± 1.0 | 3.1 ± 1.3 |
| Day, Month 9; n=16, 17, 9 | 4.0 ± 0.4 | 3.8 ± 0.9 | 3.1 ± 1.2 |
| Morning, Month 12; n=16, 16, 9 | 3.6 ± 1.2 | 3.5 ± 1.1 | 3.1 ± 1.3 |
| Day, Month 12; n=16, 16, 9 | 3.7 ± 1.0 | 3.8 ± 1.1 | 3.1 ± 1.2 |
| Morning, Month 18; n=15, 14, 10 | 3.3 ± 1.2 | 3.5 ± 1.0 | 3.4 ± 1.1 |
| Day, Month 18; n=15, 14, 10 | 3.8 ± 0.8 | 3.9 ± 0.8 | 3.5 ± 1.1 |
| Morning, Month 24; n=14, 13, 7 | 3.4 ± 1.1 | 3.5 ± 1.0 | 2.9 ± 1.3 |
| Day, Month 24; n=13, 13, 7 | 3.9 ± 0.4 | 3.9 ± 0.9 | 2.8 ± 1.5 |
| Morning, Month 30; n=9, 9, 5 | 3.4 ± 1.3 | 3.4 ± 1.0 | 3.6 ± 0.9 |
| Day, Month 30; n=9, 9, 5 | 3.8 ± 0.7 | 4.0 ± 0.5 | 3.9 ± 0.5 |
| Morning, Month 36; n=6, 11, 5 | 2.3 ± 1.3 | 3.6 ± 1.0 | 3.7 ± 0.9 |
| Day, Month 36; n=5, 11, 5 | 3.1 ± 1.3 | 4.0 ± 1.0 | 3.7 ± 0.6 |
| Morning, Endpoint; n=23, 20, 16 | 2.8 ± 1.2 | 3.4 ± 1.0 | 3.0 ± 1.0 |
| Day, Endpoint; n=23, 20, 16 | 3.4 ± 1.0 | 3.8 ± 0.9 | 3.0 ± 1.1 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "Off" time is when PD symptoms are not adequately controlled by the drug, and is represented as a percentage of total time awake per day.
| percentage of 'off' time | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 41.2 ± 19.4 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 35.4 ± 11.7 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 23.4 ± 19.7 | 30.6 ± 21.2 | 25.1 ± 12.7 |
| Day, Month 0; n=19, 20, 15 | 20.8 ± 14.6 | 21.4 ± 9.2 | 25.7 ± 12.3 |
| Morning, Month 3; n=19, 18, 13 | 26.4 ± 20.2 | 34.3 ± 20.0 | 25.7 ± 18.8 |
| Day, Month 3; n=19, 19, 13 | 23.0 ± 12.8 | 22.7 ± 13.9 | 20.2 ± 10.3 |
| Morning, Month 6; n=16, 19, 11 | 25.6 ± 21.0 | 30.1 ± 21.1 | 18.6 ± 10.9 |
| Day, Month 6; n=16, 19, 11 | 21.9 ± 13.3 | 21.8 ± 15.3 | 20.9 ± 10.7 |
| Morning, Month 9; n=16, 17, 9 | 23.9 ± 18.4 | 32.3 ± 20.5 | 23.6 ± 15.6 |
| Day, Month 9; n=16, 17, 9 | 19.5 ± 13.4 | 21.5 ± 10.8 | 22.8 ± 11.6 |
| Morning, Month 12; n=16, 16, 9 | 25.3 ± 17.8 | 28.0 ± 23.3 | 23.8 ± 16.0 |
| Day, Month 12; n=16, 16, 9 | 24.0 ± 17.3 | 19.5 ± 16.0 | 23.5 ± 9.0 |
| Morning, Month 18; n=15, 14, 10 | 21.1 ± 13.0 | 28.9 ± 21.4 | 24.9 ± 16.2 |
| Day, Month 18; n=15, 14, 10 | 17.9 ± 8.6 | 21.6 ± 13.8 | 20.1 ± 11.9 |
| Morning, Month 24; n=13, 13, 7 | 29.1 ± 21.6 | 25.4 ± 16.0 | 30.4 ± 17.9 |
| Day, Month 24; n=13, 13, 7 | 22.0 ± 15.5 | 21.3 ± 14.2 | 24.9 ± 12.2 |
| Morning, Month 30; n=9, 9, 5 | 23.4 ± 19.8 | 29.4 ± 23.1 | 28.0 ± 16.8 |
| Day, Month 30; n=9, 9, 5 | 21.6 ± 15.1 | 24.0 ± 13.4 | 23.0 ± 11.2 |
| Morning, Month 36; n=6, 11, 5 | 35.1 ± 25.2 | 29.4 ± 23.3 | 31.5 ± 15.1 |
| Day, Month 36; n=5, 11, 5 | 24.7 ± 19.4 | 18.8 ± 11.7 | 23.6 ± 12.2 |
| Morning, Endpoint; n=23, 20, 16 | 30.7 ± 22.8 | 28.5 ± 21.4 | 27.1 ± 13.8 |
| Day, Endpoint; n=23, 20, 16 | 24.8 ± 17.2 | 22.3 ± 14.2 | 25.9 ± 11.7 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "On" time is when PD symptoms are well controlled by the drug, and is represented as a percentage of total time of the last __ hours.
| percentage of 'on' time | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 40.2 ± 16.7 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 40.3 ± 14.0 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 58.4 ± 28.0 | 49.8 ± 23.1 | 55.2 ± 27.1 |
| Day, Month 0; n=19, 20, 15 | 61.8 ± 19.8 | 60.2 ± 14.8 | 46.5 ± 28.0 |
| Morning, Month 3; n=19, 18, 13 | 61.6 ± 23.6 | 52.0 ± 22.8 | 49.8 ± 28.2 |
| Day, Month 3; n=19, 19, 13 | 62.6 ± 17.8 | 58.3 ± 20.7 | 55.0 ± 26.4 |
| Morning, Month 6; n=16, 19, 11 | 57.7 ± 28.4 | 55.5 ± 24.1 | 55.8 ± 31.1 |
| Day, Month 6; n=16, 19, 11 | 62.2 ± 22.0 | 57.3 ± 21.3 | 53.2 ± 29.7 |
| Morning, Month 9; n=16, 17, 9 | 60.5 ± 25.1 | 52.3 ± 25.4 | 47.9 ± 29.4 |
| Day, Month 9; n=16, 17, 9 | 59.7 ± 23.4 | 59.5 ± 18.1 | 50.8 ± 29.2 |
| Morning, Month 12; n=16, 16, 9 | 61.1 ± 23.5 | 57.5 ± 23.4 | 49.0 ± 32.2 |
| Day, Month 12; n=16, 16, 9 | 59.5 ± 25.0 | 63.0 ± 21.9 | 51.4 ± 26.9 |
| Morning, Month 18; n=15, 14, 10 | 61.9 ± 21.4 | 55.2 ± 27.1 | 51.1 ± 33.4 |
| Day, Month 18; n=15, 14, 10 | 61.5 ± 17.9 | 57.6 ± 20.7 | 52.5 ± 31.3 |
| Morning, Month 24; n=13, 13, 7 | 61.3 ± 25.8 | 59.5 ± 23.1 | 41.3 ± 22.0 |
| Day, Month 24; n=13, 13, 7 | 62.3 ± 21.7 | 57.4 ± 23.8 | 42.7 ± 24.8 |
| Morning, Month 30; n=9, 9, 5 | 64.8 ± 28.3 | 49.3 ± 27.5 | 58.6 ± 26.3 |
| Day, Month 30; n=9, 9, 5 | 62.4 ± 27.3 | 56.9 ± 20.1 | 58.8 ± 26.6 |
| Morning, Month 36; n=6, 11, 5 | 54.5 ± 16.8 | 55.3 ± 23.4 | 51.9 ± 26.8 |
| Day, Month 36; n=5, 11, 5 | 59.1 ± 14.8 | 61.8 ± 18.8 | 55.1 ± 28.2 |
| Morning, Endpoint; n=23, 20, 16 | 52.9 ± 26.2 | 54.6 ± 21.8 | 49.9 ± 23.5 |
| Day, Endpoint; n=23, 20, 16 | 56.0 ± 21.2 | 56.5 ± 18.0 | 46.2 ± 25.7 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement, and is represented as a percentage of total time of the last __ hours.
| percentage of 'dyskinetic' time | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 18.6 ± 12.4 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 24.3 ± 14.4 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 18.2 ± 24.2 | 19.6 ± 17.8 | 19.7 ± 17.5 |
| Day, Month 0; n=19, 20, 15 | 17.4 ± 14.5 | 18.4 ± 12.5 | 27.3 ± 19.7 |
| Morning, Month 3; n=19, 18, 13 | 12.0 ± 12.0 | 13.7 ± 13.6 | 24.5 ± 20.0 |
| Day, Month 3; n=19, 19, 13 | 14.4 ± 13.0 | 18.9 ± 16.5 | 24.8 ± 21.3 |
| Morning, Month 6; n=16, 19, 11 | 16.7 ± 17.3 | 14.4 ± 12.9 | 25.6 ± 24.3 |
| Day, Month 6; n=16, 19, 11 | 15.9 ± 15.4 | 20.8 ± 16.3 | 25.8 ± 22.9 |
| Morning, Month 9; n=16, 17, 9 | 15.6 ± 13.9 | 15.5 ± 9.4 | 28.5 ± 28.0 |
| Day, Month 9; n=16, 17, 9 | 20.8 ± 15.4 | 19.0 ± 12.0 | 26.5 ± 22.8 |
| Morning, Month 12; n=16, 16, 9 | 13.6 ± 13.2 | 14.6 ± 10.4 | 27.2 ± 24.8 |
| Day, Month 12; n=16, 16, 9 | 16.2 ± 13.5 | 17.4 ± 13.8 | 25.1 ± 21.1 |
| Morning, Month 18; n=15, 14, 10 | 17.0 ± 14.5 | 15.9 ± 11.6 | 24.0 ± 22.6 |
| Day, Month 18; n=15, 14, 10 | 20.6 ± 11.9 | 20.8 ± 11.0 | 27.4 ± 21.2 |
| Morning, Month 24; n=13, 13, 7 | 9.6 ± 12.0 | 15.0 ± 11.9 | 28.2 ± 19.5 |
| Day, Month 24; n=13, 13, 7 | 15.8 ± 12.7 | 21.3 ± 19.0 | 32.4 ± 17.6 |
| Morning, Month 30; n=9, 9, 5 | 11.8 ± 20.2 | 21.3 ± 15.2 | 13.4 ± 14.8 |
| Day, Month 30; n=9, 9, 5 | 14.5 ± 16.8 | 19.1 ± 12.1 | 18.2 ± 16.9 |
| Morning, Month 36; n=6, 11, 5 | 10.4 ± 9.8 | 15.2 ± 10.3 | 16.6 ± 18.0 |
| Day, Month 36; n=5, 11, 5 | 16.2 ± 9.3 | 19.4 ± 10.8 | 21.3 ± 21.1 |
| Morning, Endpoint; n=23, 20, 16 | 16.5 ± 21.4 | 16.9 ± 11.6 | 23.0 ± 15.5 |
| Day, Endpoint; n=23, 20, 16 | 16.2 ± 9.3 | 19.4 ± 10.8 | 21.3 ± 21.1 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Off time' is when PD symptoms are not adequately controlled by the drug. Magnitude scores were 1 (worst) to 5 (best).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 2.7 ± 0.8 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 2.8 ± 0.5 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 3.6 ± 0.9 | 3.2 ± 0.9 | 3.4 ± 0.7 |
| Day, Month 0; n=19, 20, 15 | 3.6 ± 0.7 | 3.5 ± 0.6 | 3.3 ± 0.6 |
| Morning, Month 3; n=19, 18, 13 | 3.5 ± 0.8 | 2.8 ± 0.9 | 3.1 ± 0.9 |
| Day, Month 3; 19, 19, 13 | 3.6 ± 0.5 | 3.6 ± 0.7 | 3.3 ± 0.6 |
| Morning, Month 6; n=16, 19, 11 | 3.4 ± 0.9 | 3.2 ± 0.9 | 3.7 ± 0.6 |
| Day, Month 6; 16, 19, 11 | 3.8 ± 0.5 | 3.7 ± 0.6 | 3.4 ± 0.6 |
| Morning, Month 9; n=16, 17, 9 | 3.7 ± 0.8 | 3.3 ± 0.8 | 3.3 ± 0.5 |
| Day, Month 9; n=16, 17, 9 | 3.8 ± 0.5 | 3.6 ± 0.7 | 3.2 ± 0.6 |
| Morning, Month 12; n=16, 16, 9 | 3.7 ± 0.8 | 3.3 ± 1.0 | 3.4 ± 0.6 |
| Day, Month 12; n=16, 16, 9 | 3.6 ± 0.7 | 3.6 ± 0.9 | 3.4 ± 0.6 |
| Morning, Month 18; n=15, 14, 10 | 3.7 ± 0.7 | 3.3 ± 1.0 | 3.2 ± 0.7 |
| Day, Month 18; n=15, 14, 10 | 3.8 ± 0.6 | 3.7 ± 0.7 | 3.5 ± 0.7 |
| Morning, Month 24; n=13, 13, 7 | 3.6 ± 0.9 | 3.5 ± 0.8 | 3.1 ± 0.6 |
| Day, Month 24; n=13, 13, 7 | 3.7 ± 0.7 | 3.6 ± 0.7 | 3.4 ± 0.6 |
| Morning, Month 30; n=9, 9, 5 | 3.8 ± 0.9 | 3.3 ± 0.9 | 2.9 ± 0.7 |
| Day, Month 30; n=9, 9, 5 | 3.8 ± 0.8 | 3.6 ± 0.7 | 3.2 ± 0.6 |
| Morning, Month 36; n=6, 11, 5 | 3.1 ± 1.2 | 3.5 ± 0.8 | 3.2 ± 0.4 |
| Day, Month 36; n=5, 11, 5 | 3.5 ± 0.8 | 3.8 ± 0.6 | 3.0 ± 0.8 |
| Morning, Endpoint; n=23, 20, 16 | 3.3 ± 0.9 | 3.4 ± 0.8 | 3.3 ± 0.8 |
| Day, Endpoint; n=23, 20, 16 | 3.5 ± 0.7 | 3.6 ± 0.6 | 3.1 ± 0.7 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement. Magnitude scores were 1 (worst) to 5 (best).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 4.1 ± 0.8 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 3.6 ± 0.7 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 4.1 ± 0.8 | 4.1 ± 0.8 | 4.0 ± 0.6 |
| Day, Month 0; n=19, 20, 15 | 4.0 ± 0.7 | 4.0 ± 0.5 | 3.7 ± 0.8 |
| Morning, Month 3; n=19, 18, 13 | 4.4 ± 0.6 | 4.2 ± 0.5 | 4.0 ± 0.7 |
| Day, Month 3; n=19, 19, 13 | 4.2 ± 0.6 | 4.0 ± 0.6 | 3.7 ± 0.8 |
| Morning, Month 6; n=16, 19, 11 | 4.1 ± 0.6 | 4.1 ± 0.8 | 3.9 ± 0.7 |
| Day, Month 6; n=16, 19, 11 | 4.2 ± 0.6 | 3.8 ± 0.8 | 3.7 ± 0.8 |
| Morning, Month 9; n=16, 17, 9 | 4.1 ± 0.7 | 4.2 ± 0.6 | 3.7 ± 0.8 |
| Day, Month 9; n=16, 17, 9 | 3.8 ± 0.7 | 4.0 ± 0.6 | 3.8 ± 0.6 |
| Morning, Month 12; n=16, 16, 9 | 4.1 ± 0.6 | 4.2 ± 0.6 | 3.7 ± 0.7 |
| Day, Month 12; n=16, 16, 9 | 4.1 ± 0.6 | 3.7 ± 0.8 | 3.8 ± 0.7 |
| Morning, Month 18; n=15, 14, 10 | 3.9 ± 0.6 | 3.8 ± 0.7 | 3.9 ± 0.7 |
| Day, Month 18; n=15, 14, 10 | 3.9 ± 0.5 | 3.9 ± 0.4 | 3.8 ± 0.8 |
| Morning, Month 24; n=13, 13, 7 | 4.4 ± 0.6 | 4.2 ± 0.6 | 4.1 ± 0.6 |
| Day, Month 24; n=13, 13, 7 | 4.1 ± 0.6 | 3.9 ± 0.6 | 3.8 ± 0.5 |
| Morning, Month 30; n=9, 9, 5 | 4.5 ± 0.7 | 3.9 ± 0.6 | 4.2 ± 0.7 |
| Day, Month 30; n=9, 9, 5 | 4.5 ± 0.5 | 3.9 ± 0.6 | 4.1 ± 0.6 |
| Morning, Month 36; n=6, 11, 5 | 4.3 ± 0.8 | 4.0 ± 0.7 | 4.1 ± 0.6 |
| Day, Month 36; n=5, 11, 5 | 4.0 ± 0.5 | 3.7 ± 0.6 | 4.0 ± 0.7 |
| Morning, Endpoint; n=23, 20, 16 | 4.3 ± 0.8 | 4.0 ± 0.7 | 4.1 ± 0.6 |
| Day, Endpoint; 23, 20, 16 | 4.0 ± 0.7 | 3.7 ± 0.6 | 3.6 ± 0.8 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Cramps' scores were 1 (worst) to 5 (best).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 4.4 ± 0.7 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 4.5 ± 0.6 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 4.7 ± 0.4 | 4.6 ± 0.7 | 4.6 ± 0.4 |
| Day, Month 0; n=19, 20, 15 | 4.7 ± 0.4 | 4.7 ± 0.5 | 4.6 ± 0.5 |
| Morning, Month 3; n=19, 18, 13 | 4.8 ± 0.3 | 4.6 ± 0.7 | 4.5 ± 0.6 |
| Day, Month 3; n=19, 19, 13 | 4.7 ± 0.5 | 4.7 ± 0.6 | 4.5 ± 0.7 |
| Morning, Month 6; n=16, 19, 11 | 4.8 ± 0.3 | 4.5 ± 0.9 | 4.3 ± 1.2 |
| Day, Month 6; n=16, 19, 11 | 4.8 ± 0.3 | 4.5 ± 0.8 | 4.3 ± 1.1 |
| Morning, Month 9; n=16, 17, 9 | 4.8 ± 0.3 | 4.4 ± 0.7 | 4.4 ± 1.0 |
| Day, Month 9; n=16, 17, 9 | 4.7 ± 0.5 | 4.5 ± 0.7 | 4.3 ± 0.9 |
| Morning, Month 12; n=16, 16, 9 | 4.8 ± 0.3 | 4.5 ± 0.7 | 4.2 ± 1.4 |
| Day, Month 12; n=16, 16, 9 | 4.5 ± 0.7 | 4.7 ± 0.5 | 4.1 ± 1.3 |
| Morning, Month 18; n=15, 14, 10 | 4.7 ± 0.4 | 4.4 ± 0.8 | 4.1 ± 0.8 |
| Day, Month 18; n=15, 14, 10 | 4.7 ± 0.5 | 4.6 ± 0.5 | 4.3 ± 1.0 |
| Morning, Month 24; n=13, 13, 7 | 4.6 ± 0.4 | 4.8 ± 0.2 | 4.0 ± 1.4 |
| Day, Month 24; n=13, 13, 7 | 4.5 ± 0.6 | 4.8 ± 0.3 | 4.0 ± 1.3 |
| Morning, Month 30; n=9, 9, 5 | 4.9 ± 0.3 | 4.7 ± 0.4 | 4.1 ± 1.5 |
| Day, Month 30; n=9, 9, 5 | 4.9 ± 0.3 | 4.8 ± 0.2 | 3.9 ± 1.5 |
| Morning, Month 36; n=6, 11, 5 | 4.5 ± 0.4 | 4.7 ± 0.3 | 4.1 ± 1.3 |
| Day, Month 36; n=5, 11, 5 | 4.7 ± 0.6 | 4.8 ± 0.2 | 4.2 ± 1.0 |
| Morning, Endpoint; n=23, 20, 16 | 4.6 ± 0.4 | 4.5 ± 0.7 | 4.4 ± 0.8 |
| Day, Endpoint; n=23, 20, 16 | 4.5 ± 0.6 | 4.6 ± 0.5 | 4.5 ± 0.7 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Satisfied with function' scores were 1 (worst) to 5 (best).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 2.5 ± 1.0 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 2.6 ± 0.5 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 3.3 ± 0.9 | 3.2 ± 0.9 | 3.8 ± 0.8 |
| Day, Month 0; n=19, 20, 15 | 3.4 ± 0.7 | 3.4 ± 0.6 | 3.3 ± 1.0 |
| Morning, Month 3; n=19, 18, 13 | 3.4 ± 0.9 | 3.0 ± 1.1 | 3.4 ± 1.1 |
| Day, Month 3; n=19, 19, 13 | 3.5 ± 0.6 | 3.4 ± 0.8 | 3.3 ± 0.9 |
| Morning, Month 6; n=16, 19, 11 | 3.5 ± 0.9 | 3.3 ± 0.8 | 3.7 ± 0.8 |
| Day, Month 6; n=16, 19, 11 | 3.6 ± 0.6 | 3.4 ± 0.7 | 3.5 ± 0.7 |
| Morning, Month 9; n=16, 17, 9 | 3.4 ± 0.7 | 3.3 ± 0.9 | 3.6 ± 0.7 |
| Day, Month 9; n=16, 17, 9 | 3.5 ± 0.6 | 3.4 ± 0.8 | 3.4 ± 0.7 |
| Morning, Month 12; n=16, 16, 9 | 3.6 ± 0.8 | 3.4 ± 0.8 | 3.5 ± 0.8 |
| Day, Month 12; n=16, 16, 9 | 3.5 ± 0.6 | 3.6 ± 0.6 | 3.6 ± 0.7 |
| Morning, Month 18; n=15, 14, 10 | 3.4 ± 0.9 | 3.4 ± 0.8 | 3.3 ± 1.1 |
| Day, Month 18; n=15, 14, 10 | 3.5 ± 0.6 | 3.6 ± 0.5 | 3.4 ± 0.8 |
| Morning, Month 24; n=13, 13, 7 | 3.4 ± 0.9 | 3.6 ± 0.7 | 3.1 ± 0.9 |
| Day, Month 24; n=13, 13, 7 | 3.6 ± 0.6 | 3.5 ± 0.7 | 3.3 ± 0.9 |
| Morning, Month 30; n=9, 9, 5 | 3.6 ± 0.8 | 3.4 ± 0.9 | 3.6 ± 0.9 |
| Day, Month 30; n=9, 9, 5 | 3.5 ± 0.8 | 3.6 ± 0.5 | 3.6 ± 0.5 |
| Morning, Month 36; n=6, 11, 5 | 3.4 ± 0.4 | 3.3 ± 0.8 | 3.5 ± 0.9 |
| Day, Month 36; n=5, 11, 5 | 3.5 ± 0.5 | 3.5 ± 0.7 | 3.5 ± 0.8 |
| Morning, Endpoint; n=23, 20, 16 | 3.2 ± 0.7 | 3.3 ± 0.7 | 3.4 ± 0.9 |
| Day, Endpoint; n=23, 20, 16 | 3.4 ± 0.6 | 3.4 ± 0.6 | 3.1 ± 0.9 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Self-assessment' scores were -3 (Off) to +3 (dyskinetic). 'Off' time is when PD symptoms are not adequately controlled by the drug. 'Dyskinetic' time is time with involuntary muscle movement. "0" is defined as the normal ON state without dyskinesia (the desired motor state). Everything closer to "0" means improvement, everything more away from "0" means either less mobility (in the negative score) or involuntary movements (dyskinesia, in the positive score).
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | -0.9 ± 1.2 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | -0.3 ± 1.1 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | -0.4 ± 1.1 | -0.1 ± 1.0 | 0.2 ± 0.8 |
| Day, Month 0; n=19, 20, 15 | -0.2 ± 0.9 | -0.1 ± 0.6 | 0.1 ± 1.0 |
| Morning, Month 3; n=19, 18, 13 | -0.2 ± 0.9 | -0.6 ± 0.9 | 0.0 ± 0.8 |
| Day, Month 3; n=19, 19, 13 | -0.3 ± 0.7 | -0.1 ± 0.7 | 0.3 ± 1.0 |
| Morning, Month 6; n=16, 19, 11 | -0.4 ± 1.0 | -0.2 ± 1.0 | 0.3 ± 0.7 |
| Day, Month 6; n=16, 19, 11 | -0.2 ± 0.8 | 0.0 ± 0.8 | 0.3 ± 0.7 |
| Morning, Month 9; n=16, 17, 9 | -0.2 ± 0.8 | -0.4 ± 0.7 | 0.4 ± 1.0 |
| Day, Month 9; n=16, 17, 9 | 0.2 ± 0.8 | -0.0 ± 0.5 | -0.1 ± 0.6 |
| Morning, Month 12; n=16, 16, 9 | -0.3 ± 0.8 | -0.2 ± 0.9 | 0.4 ± 0.6 |
| Day, Month 12; n=16, 16, 9 | -0.3 ± 0.9 | 0.1 ± 0.8 | 0.1 ± 0.8 |
| Morning, Month 18; n=15, 14, 10 | -0.3 ± 0.8 | 0.1 ± 0.8 | -0.0 ± 0.9 |
| Day, Month 18; n=15, 14, 10 | -0.2 ± 0.7 | -0.2 ± 0.4 | 0.1 ± 0.9 |
| Morning, Month 24; n=13, 13, 7 | -0.5 ± 0.8 | -0.0 ± 0.7 | 0.1 ± 0.9 |
| Day, Month 24; n=13, 13, 7 | -0.2 ± 0.8 | -0.1 ± 0.8 | -0.0 ± 0.5 |
| Morning, Month 30; n=9, 9, 5 | -0.4 ± 1.2 | -0.2 ± 0.9 | 0.2 ± 1.1 |
| Day, Month 30; n=9, 9, 5 | -0.3 ± 0.8 | -0.3 ± 0.5 | -0.3 ± 0.5 |
| Morning, Month 36; n=6, 11, 5 | -0.9 ± 1.3 | -0.0 ± 1.2 | 0.3 ± 0.7 |
| Day, Month 36; n=5, 11, 5 | -0.2 ± 1.0 | 0.2 ± 0.5 | -0.2 ± 0.8 |
| Morning, Endpoint; n=23, 20, 16 | -0.6 ± 1.1 | -0.2 ± 1.1 | 0.2 ± 0.7 |
| Day, Endpoint; n=23, 20, 16 | -0.3 ± 1.0 | -0.0 ± 0.7 | 0.2 ± 1.0 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Free tapping is defined as voluntary repetitive finger tapping on computer-generated fields. 'Free tapping speed' is a count of the number of taps per 20 seconds.
| taps/20 seconds | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 39.9 ± 12.8 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 39.7 ± 11.2 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 44.4 ± 12.5 | 39.2 ± 14.2 | 40.6 ± 14.1 |
| Day, Month 0; n=19, 20, 15 | 43.5 ± 11.5 | 40.2 ± 12.5 | 40.3 ± 13.0 |
| Morning, Month 3; n=19, 18, 13 | 46.8 ± 15.1 | 42.2 ± 15.6 | 46.3 ± 13.6 |
| Day, Month 3; n=19, 19, 13 | 47.4 ± 13.8 | 43.2 ± 14.5 | 43.2 ± 12.9 |
| Morning, Month 6; n=16, 19, 11 | 50.7 ± 15.5 | 43.4 ± 17.5 | 48.0 ± 14.3 |
| Day, Month 6; n=16, 19, 11 | 50.3 ± 14.9 | 43.0 ± 15.8 | 47.6 ± 12.0 |
| Morning, Month 9; n=16, 17, 9 | 47.2 ± 13.3 | 45.7 ± 20.0 | 46.8 ± 16.0 |
| Day, Month 9; n=16, 17, 9 | 48.1 ± 15.7 | 48.0 ± 16.8 | 47.0 ± 15.3 |
| Morning, Month 12; n=16, 16, 9 | 49.3 ± 16.0 | 44.5 ± 16.1 | 47.0 ± 18.8 |
| Day, Month 12; n=16, 16, 9 | 48.7 ± 17.6 | 46.6 ± 15.1 | 46.6 ± 18.5 |
| Morning, Month 18; n=15, 14, 10 | 44.0 ± 14.1 | 43.1 ± 17.5 | 46.7 ± 18.9 |
| Day, Month 18; n=15, 14, 10 | 46.9 ± 12.5 | 46.3 ± 15.1 | 45.9 ± 18.1 |
| Morning, Month 24; n=13, 13, 7 | 47.3 ± 14.9 | 45.5 ± 17.6 | 38.7 ± 14.7 |
| Day, Month 24; n=13, 13, 7 | 47.6 ± 15.0 | 48.7 ± 14.2 | 41.5 ± 12.9 |
| Morning, Month 30; n=9, 9, 5 | 49.4 ± 15.7 | 42.2 ± 18.1 | 49.3 ± 22.5 |
| Day, Month 30; n=9, 9, 5 | 49.5 ± 13.0 | 42.6 ± 16.1 | 52.6 ± 19.1 |
| Morning, Month 36; n=6, 11, 5 | 46.3 ± 14.0 | 44.7 ± 18.6 | 51.4 ± 25.0 |
| Day, Month 36; n=5, 11, 5 | 45.5 ± 8.5 | 45.6 ± 19.7 | 50.5 ± 23.6 |
| Morning, Endpoint; n=23, 20, 16 | 41.8 ± 11.6 | 41.2 ± 16.8 | 43.1 ± 16.8 |
| Day, Endpoint; n=23, 20, 16 | 43.6 ± 12.1 | 43.2 ± 16.6 | 41.4 ± 15.0 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Free tapping' is defined as ____. 'Free tapping accuracy' is the percentage of accurate free taps per 20 seconds(?).
| percentage of tapping accuracy | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 70.7 ± 16.4 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 71.9 ± 14.2 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 71.4 ± 16.2 | 69.8 ± 13.8 | 63.8 ± 13.1 |
| Day, Month 0; n=19, 20, 15 | 70.1 ± 14.6 | 70.7 ± 12.4 | 65.2 ± 10.1 |
| Morning, Month 3; n=19, 18, 13 | 73.4 ± 13.0 | 70.3 ± 13.9 | 63.5 ± 13.4 |
| Day, Month 3; n=19, 19, 13 | 70.0 ± 14.4 | 69.7 ± 12.4 | 65.8 ± 12.9 |
| Morning, Month 6; n=16, 19, 11 | 67.6 ± 9.4 | 66.2 ± 13.8 | 64.8 ± 17.2 |
| Day, Month 6; n=16, 19, 11 | 65.7 ± 13.0 | 66.1 ± 12.6 | 66.7 ± 14.1 |
| Morning, Month 9; n=16, 17, 9 | 67.0 ± 13.3 | 63.6 ± 16.9 | 65.8 ± 14.2 |
| Day, Month 9; n=16, 17, 9 | 65.4 ± 9.3 | 69.9 ± 13.4 | 67.5 ± 10.9 |
| Morning, Month 12; n=16, 16, 9 | 68.7 ± 15.3 | 71.5 ± 14.4 | 61.5 ± 8.8 |
| Day, Month 12; n=16, 16, 9 | 64.7 ± 16.9 | 71.7 ± 11.9 | 60.4 ± 9.1 |
| Morning, Month 18; n=15, 14, 10 | 58.9 ± 10.8 | 65.4 ± 18.2 | 65.8 ± 13.3 |
| Day, Month 18; n=15, 14, 10 | 61.2 ± 11.0 | 69.1 ± 12.3 | 61.4 ± 12.7 |
| Morning, Month 24; n=13, 13, 7 | 62.3 ± 16.9 | 66.2 ± 16.7 | 61.9 ± 14.3 |
| Day, Month 24; n=13, 13, 7 | 64.4 ± 14.5 | 69.1 ± 15.9 | 62.4 ± 11.7 |
| Morning, Month 30; n=9, 9, 5 | 66.3 ± 10.6 | 67.2 ± 12.8 | 62.1 ± 13.6 |
| Day, Month 30; n=9, 9, 5 | 66.8 ± 12.1 | 67.3 ± 12.3 | 67.9 ± 10.5 |
| Morning, Month 36; n=6, 11, 5 | 60.7 ± 24.1 | 60.3 ± 19.3 | 61.2 ± 12.6 |
| Day, Month 36; n=5, 11, 5 | 50.3 ± 13.0 | 64.6 ± 15.5 | 63.6 ± 11.2 |
| Morning, Endpoint; n=23, 20, 16 | 63.7 ± 17.1 | 58.7 ± 17.0 | 59.3 ± 13.6 |
| Day, Endpoint; n=23, 20, 16 | 60.1 ± 15.8 | 62.7 ± 14.7 | 60.3 ± 13.7 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Tapping at increased speed - accuracy' is the percentage of accurate taps per all taps on computer-generated fields.
| percentage of accurate taps | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 74.6 ± 13.9 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 73.7 ± 14.7 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 83.7 ± 12.0 | 71.0 ± 24.8 | 73.2 ± 15.1 |
| Day, Month 0; n=19, 20, 15 | 80.4 ± 10.6 | 73.9 ± 18.6 | 73.2 ± 13.8 |
| Morning, Month 3; n=19, 18, 13 | 83.1 ± 14.8 | 73.5 ± 22.3 | 68.8 ± 22.7 |
| Day, Month 3; n=19, 19, 13 | 81.3 ± 14.5 | 74.7 ± 20.5 | 69.3 ± 20.2 |
| Morning, Month 6; n=16, 19, 11 | 87.1 ± 11.0 | 74.2 ± 22.1 | 73.3 ± 20.1 |
| Day, Month 6; n=16, 19, 11 | 87.8 ± 9.8 | 73.6 ± 20.3 | 73.0 ± 21.2 |
| Morning, Month 9; n=16, 17, 9 | 86.4 ± 11.1 | 78.2 ± 19.0 | 77.1 ± 16.9 |
| Day, Month 9; n=16, 17, 9 | 86.0 ± 10.1 | 78.8 ± 15.3 | 75.6 ± 19.0 |
| Morning, Month 12; n=16, 16, 9 | 87.0 ± 12.5 | 80.1 ± 18.6 | 74.6 ± 20.0 |
| Day, Month 12; n=16, 16, 9 | 81.8 ± 15.6 | 77.5 ± 20.9 | 72.4 ± 23.6 |
| Morning, Month 18; n=15, 14, 10 | 81.3 ± 13.9 | 77.9 ± 18.5 | 71.4 ± 25.8 |
| Day, Month 18; n=15, 14, 10 | 82.1 ± 12.9 | 78.7 ± 19.2 | 72.1 ± 24.4 |
| Morning, Month 24; n=13, 13, 7 | 85.7 ± 13.1 | 79.4 ± 20.6 | 69.0 ± 18.9 |
| Day, Month 24; n=13, 13, 7 | 85.3 ± 10.6 | 82.0 ± 15.9 | 70.0 ± 16.9 |
| Morning, Month 30; n=9, 9, 5 | 87.3 ± 5.1 | 73.5 ± 21.1 | 79.8 ± 18.1 |
| Day, Month 30; n=9, 9, 5 | 88.6 ± 6.4 | 74.5 ± 19.7 | 80.6 ± 20.5 |
| Morning, Month 36; n=6, 11, 5 | 77.9 ± 18.8 | 71.7 ± 24.9 | 81.0 ± 17.3 |
| Day, Month 36; n=5, 11, 5 | 70.7 ± 15.9 | 72.8 ± 21.8 | 77.9 ± 21.1 |
| Morning, Endpoint; n=23, 20, 16 | 79.5 ± 17.7 | 70.4 ± 23.8 | 68.0 ± 19.7 |
| Day, Endpoint; n=23, 20, 16 | 74.6 ± 17.4 | 72.0 ± 22.2 | 67.5 ± 20.5 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds.
| taps/20 seconds | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 24.5 ± 4.1 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 24.2 ± 4.2 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 26.3 ± 4.8 | 22.6 ± 5.8 | 22.7 ± 4.7 |
| Day, Month 0; n=19, 20, 15 | 26.3 ± 5.0 | 23.4 ± 5.4 | 22.0 ± 4.9 |
| Morning, Month 3; n=19, 18, 13 | 27.2 ± 5.1 | 23.8 ± 5.9 | 24.3 ± 3.5 |
| Day, Month 3; n=19, 19, 13 | 27.2 ± 4.7 | 24.4 ± 6.3 | 24.0 ± 3.9 |
| Morning, Month 6; n=16, 19, 11 | 28.3 ± 4.7 | 24.2 ± 5.3 | 24.4 ± 4.1 |
| Day, Month 6; n=16, 19, 11 | 28.2 ± 4.5 | 24.4 ± 5.3 | 25.3 ± 4.2 |
| Morning, Month 9; n=16, 17, 9 | 27.2 ± 4.1 | 24.4 ± 5.4 | 25.0 ± 5.0 |
| Day, Month 9; n=16, 17, 9 | 27.0 ± 4.5 | 25.6 ± 4.4 | 25.6 ± 4.7 |
| Morning, Month 12; n=16, 16, 9 | 27.2 ± 5.4 | 25.5 ± 5.1 | 23.8 ± 5.4 |
| Day, Month 12; n=16, 16, 9 | 26.3 ± 5.3 | 26.4 ± 4.9 | 24.7 ± 5.5 |
| Morning, Month 18; n=15, 14, 10 | 26.2 ± 4.1 | 24.9 ± 6.4 | 24.8 ± 6.1 |
| Day, Month 18; n=15, 14, 10 | 26.3 ± 3.7 | 25.9 ± 6.1 | 25.0 ± 7.0 |
| Morning, Month 24; n=13, 13, 7 | 27.0 ± 5.2 | 24.8 ± 5.6 | 22.7 ± 5.1 |
| Day, Month 24; n=13, 13, 7 | 26.7 ± 5.6 | 26.5 ± 5.1 | 23.8 ± 4.6 |
| Morning, Month 30; n=9, 9, 5 | 27.4 ± 4.6 | 24.4 ± 6.1 | 25.1 ± 7.0 |
| Day, Month 30; n=9, 9, 5 | 27.9 ± 4.2 | 25.1 ± 5.8 | 27.0 ± 5.3 |
| Morning, Month 36; n=6, 11, 5 | 26.5 ± 5.3 | 23.1 ± 6.7 | 25.1 ± 6.8 |
| Day, Month 36; n=5, 11, 5 | 25.2 ± 2.4 | 23.9 ± 6.3 | 26.3 ± 6.3 |
| Morning, Endpoint; n=23, 20, 16 | 25.1 ± 5.5 | 22.7 ± 6.3 | 22.8 ± 5.2 |
| Day, Endpoint; 23, 20, 16 | 25.1 ± 4.8 | 23.6 ± 6.2 | 23.0 ± 6.3 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds. 'Tapping random chase - accuracy' is the percentage of accurate random chase taps.
| percentage of accurate taps | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 92.0 ± 14.2 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 91.8 ± 7.8 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 94.6 ± 4.5 | 90.0 ± 12.6 | 92.6 ± 6.3 |
| Day, Month 0; n=19, 20, 15 | 92.9 ± 6.8 | 91.3 ± 10.6 | 92.3 ± 7.0 |
| Morning, Month 3; n=19, 18, 13 | 90.5 ± 17.3 | 89.2 ± 11.6 | 89.1 ± 10.1 |
| Day, Month 3; n=19, 19, 13 | 92.5 ± 9.8 | 88.6 ± 13.6 | 89.8 ± 8.0 |
| Morning, Month 6; n=16, 19, 11 | 95.2 ± 4.4 | 89.0 ± 14.2 | 90.5 ± 7.7 |
| Day, Month 6; n=16, 19, 11 | 94.6 ± 3.5 | 88.7 ± 14.0 | 89.2 ± 11.6 |
| Morning, Month 9; n=16, 17, 9 | 91.2 ± 8.1 | 90.8 ± 10.5 | 91.8 ± 6.3 |
| Day, Month 9; n=16, 17, 9 | 92.4 ± 7.7 | 93.1 ± 7.2 | 92.5 ± 4.8 |
| Morning, Month 12; n=16, 16, 9 | 92.2 ± 8.8 | 90.7 ± 11.4 | 90.6 ± 5.9 |
| Day, Month 12; n=16, 16, 9 | 91.2 ± 7.6 | 92.5 ± 8.0 | 89.2 ± 7.9 |
| Morning, Month 18; n=15, 14, 10 | 90.2 ± 11.3 | 88.8 ± 14.6 | 86.8 ± 13.9 |
| Day, Month 18; n=15, 14, 10 | 91.6 ± 5.5 | 92.1 ± 9.2 | 85.4 ± 15.4 |
| Morning, Month 24; n=13, 13, 7 | 91.7 ± 10.2 | 92.2 ± 9.6 | 89.0 ± 7.7 |
| Day, Month 24; n=13, 13, 7 | 92.9 ± 6.7 | 93.4 ± 5.2 | 90.7 ± 6.3 |
| Morning, Month 30; n=9, 9, 5 | 95.1 ± 3.3 | 85.9 ± 11.5 | 90.5 ± 9.1 |
| Day, Month 30; n=9, 9, 5 | 93.6 ± 4.9 | 88.6 ± 8.6 | 91.2 ± 7.2 |
| Morning, Month 36; n=6, 11, 5 | 83.5 ± 19.8 | 85.9 ± 14.8 | 89.7 ± 7.0 |
| Day, Month 36; n=5, 11, 5 | 82.1 ± 16.9 | 88.4 ± 11.8 | 88.8 ± 7.5 |
| Morning, Endpoint; n=23, 20, 16 | 87.8 ± 18.7 | 83.8 ± 15.1 | 87.5 ± 8.1 |
| Day, Endpoint; n=23, 20, 16 | 87.3 ± 12.6 | 86.6 ± 14.3 | 86.7 ± 9.6 |
The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Drawing impairment was assessed as a spiral score, where the participant is asked to draw a spiral. 1 is worst score, 10 is best.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Morning, Baseline (Month -3); n=20, 0, 0 | 4.0 ± 1.4 | NA ± NA | NA ± NA |
| Day, Baseline (Month -3); n=20, 0, 0 | 4.0 ± 1.2 | NA ± NA | NA ± NA |
| Morning, Month 0; n=19, 20, 15 | 4.1 ± 1.4 | 4.5 ± 1.6 | 5.0 ± 1.2 |
| Day, Month 0; n=19, 20, 15 | 4.2 ± 1.3 | 4.3 ± 1.5 | 5.1 ± 1.2 |
| Morning, Month 3; n=19, 18, 13 | 3.6 ± 1.2 | 4.3 ± 1.5 | 4.7 ± 1.5 |
| Day, Month 3; n=19, 19, 13 | 3.8 ± 1.2 | 4.2 ± 1.4 | 4.8 ± 1.5 |
| Morning, Month 6; n=16, 19, 11 | 3.8 ± 1.3 | 4.5 ± 1.7 | 4.5 ± 1.4 |
| Day, Month 6; n=16, 19, 11 | 4.1 ± 1.0 | 4.6 ± 1.6 | 4.5 ± 1.7 |
| Morning, Month 9; n=16, 17, 9 | 4.3 ± 1.2 | 4.1 ± 1.4 | 4.6 ± 1.5 |
| Day, Month 9; n=16, 17, 9 | 4.3 ± 1.0 | 4.1 ± 1.2 | 4.5 ± 1.5 |
| Morning, Month 12; n=16, 16, 9 | 4.1 ± 1.5 | 4.1 ± 1.2 | 5.0 ± 1.4 |
| Day, Month 12; n=16, 16, 9 | 4.4 ± 1.2 | 4.1 ± 1.3 | 4.7 ± 1.4 |
| Morning, Month 18; n=15, 14, 10 | 4.6 ± 1.3 | 4.4 ± 1.5 | 5.4 ± 1.8 |
| Day, Month 18; n=15, 14, 10 | 4.6 ± 1.0 | 4.3 ± 1.5 | 4.9 ± 1.8 |
| Morning, Month 24; n=13, 13, 7 | 4.3 ± 1.5 | 3.9 ± 1.3 | 5.2 ± 1.7 |
| Day, Month 24; n=13, 13, 7 | 4.5 ± 1.4 | 3.9 ± 1.1 | 5.1 ± 1.7 |
| Morning, Month 30; n=9, 9, 5 | 4.1 ± 1.4 | 4.4 ± 1.5 | 4.9 ± 1.5 |
| Day, Month 30; n=9, 9, 5 | 4.5 ± 1.2 | 4.4 ± 1.4 | 4.8 ± 1.9 |
| Morning, Month 36; n=6, 11, 5 | 4.4 ± 1.6 | 4.8 ± 1.8 | 5.3 ± 1.6 |
| Day, Month 36; n=5, 11, 5 | 5.0 ± 0.9 | 4.6 ± 1.5 | 5.3 ± 1.3 |
| Morning, Endpoint; n=23, 20, 16 | 4.5 ± 1.4 | 5.0 ± 1.8 | 5.3 ± 1.3 |
| Day, Endpoint; n=23, 20, 16 | 4.8 ± 1.2 | 4.9 ± 1.7 | 5.3 ± 1.2 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 43.1 ± 16.7 | 46.2 ± 17.3 | 47.8 ± 16.4 |
| Month 3; n=24, 22, 18 | 42.4 ± 19.1 | 45.5 ± 18.2 | 46.8 ± 16.4 |
| Month 6; n=25, 22, 18 | 43.3 ± 21.4 | 43.5 ± 17.6 | 47.4 ± 13.2 |
| Month 9; 5, 20, 17 | 40.8 ± 22.4 | 45.1 ± 13.0 | 48.1 ± 17.8 |
| Month 18; n=24, 20, 17 | 45.2 ± 22.8 | 44.2 ± 16.1 | 48.5 ± 18.0 |
| Month 24; n=23, 18, 15 | 44.5 ± 25.3 | 40.2 ± 15.9 | 52.7 ± 15.5 |
| Month 30; n=23, 17, 13 | 47.1 ± 25.5 | 47.4 ± 19.0 | 50.2 ± 19.8 |
| Month 36; n=21, 16, 12 | 46.2 ± 27.8 | 47.1 ± 14.3 | 54.0 ± 25.3 |
| Endpoint visit; n=27, 22, 18 | 47.9 ± 25.8 | 50.8 ± 17.5 | 55.0 ± 23.0 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 2.4 ± 1.8 | 2.0 ± 1.8 | 2.7 ± 1.8 |
| Month 3; n=24, 22, 18 | 2.5 ± 1.7 | 2.0 ± 1.6 | 3.2 ± 2.3 |
| Month 6; n=25, 22, 18 | 2.9 ± 1.9 | 2.3 ± 1.8 | 2.9 ± 2.1 |
| Month 9; n=25, 20, 17 | 3.0 ± 1.9 | 2.9 ± 1.6 | 3.3 ± 2.3 |
| Month 18; n=24, 20, 17 | 4.1 ± 3.0 | 2.7 ± 2.2 | 3.3 ± 2.6 |
| Month 24; n=23, 18, 15 | 3.9 ± 2.8 | 3.0 ± 2.0 | 3.5 ± 2.1 |
| Month 30; n=23, 17, 13 | 4.1 ± 3.2 | 3.5 ± 2.7 | 2.8 ± 2.0 |
| Month 36; n=21, 16, 12 | 3.9 ± 3.1 | 3.9 ± 2.5 | 3.8 ± 3.3 |
| Endpoint visit; n=27, 22, 18 | 3.9 ± 3.2 | 3.5 ± 2.6 | 4.0 ± 2.8 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 12.3 ± 5.1 | 13.7 ± 6.3 | 15.4 ± 5.9 |
| Month 3; n=24, 22, 18 | 12.0 ± 5.7 | 12.8 ± 7.1 | 15.0 ± 5.8 |
| Month 6; n=25, 22, 18 | 12.4 ± 6.7 | 13.4 ± 6.7 | 14.3 ± 4.4 |
| Month 9; n=25, 20, 17 | 11.8 ± 6.9 | 13.0 ± 5.5 | 14.4 ± 5.2 |
| Month 18; n=24, 20, 17 | 13.3 ± 7.2 | 12.9 ± 6.6 | 15.6 ± 5.8 |
| Month 24; n=23, 18, 15 | 12.9 ± 7.7 | 12.2 ± 6.2 | 17.2 ± 5.3 |
| Month 30; n=23, 17, 13 | 14.0 ± 8.5 | 14.6 ± 7.3 | 16.9 ± 6.3 |
| Month 36; n=21, 16, 12 | 13.9 ± 8.4 | 14.6 ± 5.4 | 16.8 ± 8.2 |
| Endpoint visit; n=27, 22, 18 | 14.6 ± 7.9 | 15.7 ± 6.4 | 17.3 ± 7.0 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 22.0 ± 9.7 | 23.4 ± 11.1 | 22.4 ± 9.8 |
| Month 3; n=24, 22, 18 | 21.6 ± 11.5 | 22.9 ± 11.3 | 21.9 ± 9.5 |
| Month 6; n=25, 20, 18 | 21.5 ± 14.1 | 22.8 ± 9.9 | 22.6 ± 8.6 |
| Month 9; n=25, 20, 17 | 19.9 ± 12.4 | 21.9 ± 8.1 | 22.9 ± 11.8 |
| Month 18; n=24, 20, 16 | 21.3 ± 12.6 | 21.7 ± 9.3 | 23.3 ± 11.1 |
| Month 24; n=23, 18, 15 | 21.4 ± 14.2 | 18.2 ± 9.8 | 25.4 ± 9.2 |
| Month 30; n=23, 17, 13 | 23.1 ± 15.6 | 22.6 ± 11.5 | 24.0 ± 12.1 |
| Month 36; n=21, 16, 12 | 22.0 ± 17.2 | 22.2 ± 7.9 | 28.0 ± 15.8 |
| Endpoint visit; n=27, 22, 17 | 23.1 ± 15.8 | 24.1 ± 9.8 | 28.6 ± 13.6 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Part IV, questions are measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect) or 2-point scale (0 or 1). Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Higher scores are associated with more disability.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 6.5 ± 2.7 | 7.1 ± 3.4 | 7.2 ± 3.0 |
| Month 3; n=24, 22, 18 | 6.3 ± 2.9 | 7.8 ± 3.1 | 6.7 ± 3.4 |
| Month 6; n=25, 22, 18 | 6.5 ± 2.7 | 7.1 ± 2.8 | 7.7 ± 3.2 |
| Month 9; n=25, 20, 17 | 6.1 ± 3.3 | 7.3 ± 3.3 | 7.5 ± 4.2 |
| Month 18; n=24, 20, 17 | 6.5 ± 3.3 | 7.0 ± 3.2 | 7.6 ± 2.8 |
| Month 24; n=23, 18, 15 | 6.3 ± 4.3 | 6.8 ± 3.6 | 6.6 ± 2.5 |
| Month 30; n=22, 17, 13 | 6.2 ± 3.7 | 6.6 ± 3.3 | 6.5 ± 2.8 |
| Month 36; n=21, 16, 12 | 6.4 ± 3.0 | 6.4 ± 2.4 | 5.5 ± 1.8 |
| Endpoint visit; n=26, 22, 18 | 6.5 ± 3.0 | 7.5 ± 3.0 | 6.7 ± 2.7 |
The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 0.67 ± 0.27 | 0.68 ± 0.27 | 0.62 ± 0.24 |
| Month 3; n=24, 22, 18 | 0.61 ± 0.30 | 0.70 ± 0.29 | 0.57 ± 0.32 |
| Month 6; n=25, 21, 18 | 0.64 ± 0.26 | 0.71 ± 0.22 | 0.57 ± 0.32 |
| Month 9; n=25, 20, 17 | 0.61 ± 0.33 | 0.66 ± 0.23 | 0.59 ± 0.30 |
| Month 18; n=24, 20, 16 | 0.64 ± 0.23 | 0.66 ± 0.34 | 0.53 ± 0.35 |
| Month 24; n=21, 18, 15 | 0.58 ± 0.33 | 0.67 ± 0.26 | 0.47 ± 0.32 |
| Month 30; n=22, 17, 12 | 0.55 ± 0.28 | 0.69 ± 0.19 | 0.52 ± 0.28 |
| Month 36; n=21, 15, 11 | 0.52 ± 0.31 | 0.57 ± 0.28 | 0.51 ± 0.25 |
| Endpoint visit; n=26, 22, 17 | 0.54 ± 0.31 | 0.60 ± 0.25 | 0.46 ± 0.33 |
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'
| units on a scale | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Month 0; n=27, 22, 18 | 0.68 ± 0.18 | 0.65 ± 0.18 | 0.58 ± 0.23 |
| Month 3; n=24, 22, 18 | 0.65 ± 0.19 | 0.63 ± 0.18 | 0.58 ± 0.20 |
| Month 6; n=25, 21, 18 | 0.60 ± 0.22 | 0.65 ± 0.16 | 0.59 ± 0.18 |
| Month 9; n=25, 20, 17 | 0.68 ± 0.14 | 0.69 ± 0.15 | 0.58 ± 0.19 |
| Month 18; n=24, 20, 16 | 0.62 ± 0.20 | 0.60 ± 0.20 | 0.55 ± 0.27 |
| Month 24; n=21, 17, 15 | 0.64 ± 0.18 | 0.60 ± 0.20 | 0.63 ± 0.12 |
| Month 30; n=22, 17, 12 | 0.56 ± 0.20 | 0.67 ± 0.14 | 0.65 ± 0.17 |
| Month 36; n=21, 15, 11 | 0.56 ± 0.17 | 0.61 ± 0.18 | 0.62 ± 0.19 |
| Endpoint visit; n=26, 22, 17 | 0.57 ± 0.16 | 0.61 ± 0.17 | 0.57 ± 0.21 |
Collected over Events presented are treatment-emergent (those with a start date beyond or equal to first day of study treatment but within 7 days [for adverse events] or 30 days [for serious adverse events] after last study drug intake). Treatment period was 36 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Duodopa Naïve | — | 24/36 (66.7%) | 29/36 (80.6%) |
| Duodopa Non-naïve < 2 Years | — | 17/22 (77.3%) | 22/22 (100%) |
| Duodopa Non-naïve ≥ 2 Years | — | 14/18 (77.8%) | 17/18 (94.4%) |
| Event | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Medical device changeSurgical and medical procedures | 9/36 | 9/22 | 3/18 |
| PneumoniaInfections and infestations | 4/36 | 3/22 | 1/18 |
| FallInjury, poisoning and procedural complications | 1/36 | 3/22 | 2/18 |
| Medical device removalSurgical and medical procedures | 0/36 | 3/22 | 0/18 |
| Medical device complicationInjury, poisoning and procedural complications | 1/36 | 0/22 | 2/18 |
| DehydrationMetabolism and nutrition disorders | 1/36 | 0/22 | 2/18 |
| DyskinesiaNervous system disorders | 2/36 | 1/22 | 2/18 |
| HallucinationPsychiatric disorders | 4/36 | 1/22 | 1/18 |
| AnaemiaBlood and lymphatic system disorders | 1/36 | 2/22 | 1/18 |
| Femur fractureInjury, poisoning and procedural complications | 0/36 | 2/22 | 0/18 |
| Event | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years |
|---|---|---|---|
| Device dislocationInjury, poisoning and procedural complications | 7/36 | 8/22 | 5/18 |
| Blood homocysteine increasedInvestigations | 2/36 | 4/22 | 6/18 |
| Excessive granulation tissueSkin and subcutaneous tissue disorders | 6/36 | 7/22 | 2/18 |
| Device related infectionInfections and infestations | 4/36 | 6/22 | 4/18 |
| Micturition urgencyRenal and urinary disorders | 0/36 | 6/22 | 2/18 |
| Medical device changeSurgical and medical procedures | 6/36 | 5/22 | 1/18 |
| ConstipationGastrointestinal disorders | 8/36 | 3/22 | 4/18 |
| Urinary tract infectionInfections and infestations | 2/36 | 4/22 | 4/18 |
| DepressionPsychiatric disorders | 7/36 | 4/22 | 2/18 |
| HallucinationPsychiatric disorders | 7/36 | 2/22 | 2/18 |
| Age, Continuous(years) | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Mean | 64.6 ± 6.4 | 65.4 ± 5.2 | 66.6 ± 8.7 | 65.4 ± 6.8 |
| Sex: Female, Male(Participants) | Duodopa Naïve | Duodopa Non-naïve < 2 Years | Duodopa Non-naïve ≥ 2 Years | Total |
|---|---|---|---|---|
| Female | 11 | 7 | 6 | 24 |
| Male | 16 | 15 | 12 | 43 |
No study locations are listed for this record.
The record gives a start of Mar 2006, a primary completion of Mar 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie (prior sponsor, Abbott) →